Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
you gonna do OTC and PINK?
TES 2.25 American Telecom Services Expands Into South American Market Through Prominent International Distributor; Precision Trading Corp.
Precision, one of the largest exporters of consumer electronics to South and Central America, adds ATS phones to its line of major brand offerings
Jun 20, 2007 8:00:00 AM
CITY OF INDUSTRY, Calif., June 20 /PRNewswire-FirstCall/ -- American Telecom Services Inc. (Amex: TES), a provider of converged communications solutions, today announced a new and expansive relationship with Precision Trading Corp., one of the largest exporters and distributors of consumer electronics and housewares to South and Central America, as well as the Caribbean. Precision will open these markets to American Telecom Services through the distribution of three DECT 6.0 Cordless Phones as part of an initial launch. All packaging on these phones will be trilingual: Spanish, Portuguese, and English; appealing to the maximum number of potential consumers in these key regions.
Precision will initially target Columbia, Venezuela, Uruguay, Ecuador and Argentina, among others, for the sale of ATS traditional DECT 6.0 telephone systems.
Precision Trading of Miami Florida currently distributes major brands such as Panasonic, Sharp Toshiba within the target markets. Precision possesses a network of distributors and service stations in most major countries throughout Latin America.
Bruce Hahn, American Telecom Service's Chief Executive Officer, commented, "As we continue to build our brand domestically, we recognize there is strong international demand for our product and service offerings. To rapidly penetrate these new markets, we are excited to partner with a proven exporter and distributor like Precision Trading Corp. We look forward to combining our exceptional quality and money-saving value proposition with Precision's worldwide network and long-standing reputation for quality and integrity. Soon, consumers throughout the Caribbean, South and Central America will be able to call friends and family around the world, with the newest DECT 6.0 telephone technology. We look forward to a long and mutually beneficial relationship with Precision Trading Corp."
The initial launch will focus on telephone answering devices as well as affordable DECT multi handset phones.
Simon Beda, President of Precision Trading Corp. added, "We believe that consumers throughout the regions we serve will be receptive to American Telecom Services state-of-the-art cordless telephones using interference-free DECT 6.0 technology. We are pleased that ATS has worked with us to create packaging that will enable effective distribution of these innovative phones throughout Central and South America, as well as the Caribbean."
About Precision Trading Corp.
Precision Trading Corp. was founded in 1979 with the goal of becoming the premier exporter and distributor of consumer electronics and housewares in the Americas. Precision's main goal has been and continues to be to offer the best products at the best prices while adhering to the highest ethical standards as well as total customer satisfaction. Precision Trading is located in Miami, Florida, where its headquarters as well as its main warehouse and distribution facilities are located. In Brazil, Precision has a joint venture audio and video manufacturing facility in the free port city of Manaus. Worldwide purchasing is managed out of Miami headquarters with the assistance of satellite purchasing offices in Hong Kong and Ningbo, P.R.C. For more information, visit http://www.precisiontrading.com/ online.
About American Telecom Services
American Telecom Services, a leader in converged communications solutions, provides consumers "Good Reasons to Pick up the Phone." American Telecom Services combines state-of-the-art telephones bundled with a variety of pre-paid long distance and Voice over Internet Protocol (VoIP or Internet Phone) calling plans designed to save consumers up to 60% on long distance costs. The Company offers the only home phones bundled with Pay N' Talk prepaid residential long-distance services powered by IDT Telecom (patent-pending) and is the only provider of DigitalClear(TM) Internet phones that include an adapter and router built right into the base of the phones (patent-pending); Just "Plug In & Save!" The DigitalClear product line offers consumers the opportunity to save up to $500 on their phone services using Internet Phone technology supplied by leading technology providers. Consumers can select phones bundled with SunRocket services, and enjoy SunRocket's Bottom-Line Pricingsm with plans free of bogus charges, tacked-on fees, and other unpleasant surprises that normally show up on phone bills. Consumers can also chose phones bundled with Lingo Internet phone service and enjoy one of the most affordable U.S. Internet phone services. Consumers who do not possess high-speed Internet service at home, all DigitalClear products also include a high speed Internet offer from Broadband National, creating a "One Box Solution" to be sold at retail. American Telecom Service's products are available nationally at more than 13,000 retail locations. Visit www.atsphone.com for Company and product information.
Safe Harbor Statement
Any statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify those forward-looking statements by words such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of those words and some other comparable words. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from historical results or those the Company anticipates. Factors that could cause actual results to differ from those contained in the forward-looking statement include, but are not limited to, those risks and uncertainties described in the Company's prospectus dated December 11, 2006 and the other reports and documents the Company files from time to time with the Securities and Exchange Commission. Statements included in this press release are based upon information known to the Company as of the date of this press release, and the Company assumes no obligation to (and expressly disclaims any such obligation to) publicly update or alter its forward-looking statements made in this press release, whether as a result of new information, future events or otherwise, except as otherwise required by applicable federal securities laws.
Contact: Company Investors:
Bruce Hahn, CEO Brett Maas
(310) 871-9904 Hayden Communications
(404) 261-7466 (646) 536-7331
Bruce.Hahn@atsphone.com brett@haydenir.com
SOURCE American Telecom Services Inc.
----------------------------------------------
Bruce Hahn
CEO of American Telecom Services Inc.
+1-310-871-9904
or +1-404-261-7466
Bruce.Hahn@atsphone.com; or Investors
Brett Maas of Hayden Communications
+1-646-536-7331
brett@haydenir.com
for American Telecom Services Inc.
HALO 10.14 Halozyme Therapeutics to Present at the Jefferies Healthcare Conference
Jun 20, 2007 8:00:00 AM
SAN DIEGO, June 20 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will present at the Jefferies Healthcare Conference to be held in New York on June 26-28, 2007.
Jonathan Lim, MD, Halozyme's President and Chief Executive Officer, will present on Wednesday, June 27, 2007 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time) and will discuss the Company's strategic initiatives, product pipeline and market opportunities.
Interested parties can access a live audio webcast and slide presentation via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.halozyme.com. An archived presentation will be available on the Web site for 30 days.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition, the company has received FDA approval for two products: Cumulase(R) and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.
SOURCE Halozyme Therapeutics, Inc.
----------------------------------------------
David A. Ramsay
Chief Financial Officer of Halozyme Therapeutics
Inc.
+1-858-794-8881
dramsay@halozyme.com; or investor relations
Don Markley of Lippert\Heilshorn & Associates
+1-310-691-7100
dmarkley@lhai.com
for Halozyme Therapeutics
Inc.
UVSE 1.93 Universal Energy Corp. Drilling Gains Significance as Iran Issues Threats
Jun 20, 2007 8:00:00 AM
HOUSTON, June 20 /PRNewswire-FirstCall/ -- Universal Energy Corp. (OTC Bulletin Board: UVSE.OB) announced today final plans for the company's aggressive summer drilling program that has gained market significance due to recent negative developments in U.S. relations with Iran and OPEC.
Earlier this week, the company announced site preparation at the Louisiana Amberjack prospect and plans to spud the well within the next two weeks. Two additional domestic drilling programs will be underway this summer at the Lake Campo and Caviar prospects, also in Louisiana.
In light of two recent political developments, domestic drilling prospects now become even more essential for the future of the American oil supply. Yesterday, Iran issued a threat to cut off oil exports to the U.S. in retaliation of U.S. Government demands that they cease nuclear testing. In Washington, Congress has been working to pass legislation that will allow the U.S. to sue the OPEC oil producers for price manipulation. Both actions would drive up oil prices, decisively, over the current nine-month highs, and immediately reduce supply.
In an interview on Tuesday with the Iranian Newspaper, Sharq; Iran's OPEC Governor, Hossein Kazempour Ardebili stated "Definitely, the market will be faced with a new shock and oil prices will increase strongly". The quote came during a question regarding the impact of Iran ceasing oil exports to the United States.
Billy Raley, CEO of Universal Energy Corp., stated, "it is reality that domestic oil and gas producers are becoming increasingly more important as tensions in the Middle East continue to escalate." Raley continued, "As a country, our future energy needs depend on continued discovery and extraction of oil and gas, right here in the United States. Our company is committed to helping make that happen."
Universal invests in prolific areas within the United States and Canada by acquiring low risk in-field oil and gas rights that offset existing production. The Louisiana prospects the company is currently drilling this summer, include properties that contain proven but undeveloped reserves analyzed by 3-D Seismic surveys and other research techniques to help lower drilling risks.
About Universal Energy Corp. - Universal Energy Corp. is an energy company engaged in the acquisition and development of crude oil and natural gas leases in the United States and Canada. We pursue oil and gas prospects in partnership with oil and gas companies with exploration, development and production expertise. Our prospect areas consist of lands in Alberta, Canada and Southeastern Louisiana. Visit www.universalenergycorp.info for more details.
Safe Harbor Statement
All statements, other than statements of historical fact, included in this press release are forward-looking statements within the meaning of the private securities Litigation Reform Act of 1995. The forward-looking statements, including statements about the company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the company and factors that are subject to uncertainties, risk and other influences, which are outside the company's control, and may yield results differing materially from those anticipated. The Company makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors but they include and are not limited to the existence of underground deposits of commercial quantities of oil and gas; cessation or delays in exploration opportunities being fewer than currently anticipated. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings.
SOURCE Universal Energy Corp.
----------------------------------------------
Billy Raley
CEO
of Universal Energy Corp.
800-975-2076
braley@universalenergycorp.info
SWME .0042 Swiss Medica Announces Corporate Update
Jun 20, 2007 8:00:00 AM
TORONTO, June 20 /PRNewswire-FirstCall/ -- Swiss Medica, Inc. (OTC Bulletin Board: SWME) announced today that
1) Swiss Medica recently filed its 10KSB for the year ended December 31,
2006 and its 10QSB for the 3 months ended March 31, 2007 with the
Securities & Exchange Commission. The filings are accessible in the
investor relation's section of www.swissmedica.com.
2) As Swiss Medica Inc. has now filed the outstanding 10KSB and 10QSB,
it is current with its filings and its symbol has now been changed
back to SWME.OB.
3) Swiss Medica has been undertaking a large restructuring of its
operations and management, which has included staff reductions, cost
cutting and a refocusing of its distribution strategy. Details of
this operational restructuring are included in recent S.E.C. filings.
In addition, Swiss Medica will be issuing further press releases
outlining its strategic repositioning as well as management
restructuring.
4) Swiss Medica has also undertaken a restructuring of its balance sheet
with a focus on debt restructuring and debt reduction. Details of
these debt restructurings have been included in recent S.E.C. filings
with further restructuring transaction details to be included in
press releases and S.E.C. filings in the weeks to come.
5) Swiss Medica has been raising capital to undertake the restructuring,
reduce its debt and implement its strategic repositioning program.
Details of these financing activities will be included in S.E.C.
filings including the 8K filed with the S.E.C. on May 29, 2007.
Swiss Medica will make further announcements with respect to details of its restructuring plans.
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our websites at www.swissmedica.com and www.O24zone.com
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica also launched the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
SOURCE Swiss Medica, Inc.
----------------------------------------------
Swiss Medica
Inc. Inquiries
+1-905-501-0553
ATML 5.43 Atmel Extends its AVR 32-bit MCU Family
64- and 48-pin Flash Microcontrollers with USB OTG
Jun 20, 2007 8:00:00 AM
SAN JOSE, Calif., June 20 /PRNewswire/ -- Atmel(R) Corporation (Nasdaq: ATML) introduced today a second family based on the AVR(R)32 UC core, its 32-bit Flash microcontroller with DSP extensions. Developed for low power PC-centric applications, the AVR32 UC3B Series of MCUs has Full-Speed (12 Mbps) USB 2.0 with On-The-Go (OTG) capability. On-chip SRAM ranges from 16K bytes to 32K bytes and on-chip Flash from 64K bytes to 256K bytes.
The AVR32 UC3B Series provides extended communication capability, excellent computational performance and low power consumption in a tiny form factor. The family targets applications such as appliance control, security systems, industrial control & automation and PC peripherals.
The new AVR32 UC3B devices deliver 72 Dhrystone MIPS (DMIPS) at 60 MHz, include true single-cycle MACs and DSP arithmetic and consume only 23 mA at 3.3V. With power consumption as low as 1 mW/DMIPS, UC3B Series MCUs outperform by a ratio of 3 any other available architectures offering similar features. The standby power consumption of UC3B Series is just 30 micro-Amps using a single 3.3V power supply and below 15 micro-Amps when the dual power supply (1.8V/3.3V) is used.
The AVR32 UC3B Full-Speed USB 2.0 interface allows communication with PCs through various USB classes such as Human Interface Device (HID) class for serial data communication or mass-storage class for larger bulk data transfers. The On-The-Go (OTG) capability changes a USB device into a USB host on-the-fly, enabling peer-to-peer communication between two USB devices. The UC3B Series also feature a 10-bit Analog-to-Digital converter (ADC), one serial programming interface (SPI), synchronous serial interface (SSC), I2C-compatible two-wire interface (TWI), three UARTs, three general purpose timers, seven pulse width modulators (PWM) and a full set of supervisory functions.
UC3B Series MCUs have DMA enabled peripherals with a seven-channel peripheral DMA controller, and a five-layer high speed bus matrix with point-to-point connections from all masters to all slaves at a maximum speed of 240M bytes/s at 60 MHz each.
Development Tools -- Atmel provides the AVR32 GNU C tool chain and FreeRTOS.org real-time kernel free of charge. Commercial software is also available including: IAR(R) (C compiler -- Embedded Workbench), ExpressLogic (Real-time Operating System -- ThreadX(R)) and Micrium (Real-time Operating System -- uCOS/II).
Atmel's AVR32 Studio and AVR JTAGICE mkII, provide the AVR32 UC3B Series with a multiplatform integrated development environment (IDE) already configured for the GNU tool chain, including support for advanced debugging sessions with data and code trace using the AVR32's Nano Trace or Nexus class 2+ interface. The ATEVK1101 kit is available for AVR32 UC3B Series evaluation.
Availability and Pricing -- The two first devices of the UC3B series are sampling now. The AT32UC3B0256, with OTG, is packaged in a 64-pin QFP/QFN and the AT32UC3B1256, without OTG capability, is packaged in a 48-pin QFP/QFN. The AT32UC3B0256 and AT32UC3B1256 in a QFP package are priced at US $4.96 and US $4.66 respectively in 10,000 quantities.
About Atmel
Atmel is a worldwide leader in the design and manufacture of microcontrollers, advanced logic, mixed-signal, nonvolatile memory and radio frequency (RF) components. Leveraging one of the industry's broadest intellectual property (IP) technology portfolios, Atmel is able to provide the electronics industry with complete system solutions focused on consumer, industrial, security, communications, computing and automotive markets.
(C) 2007 Atmel Corporation. All Rights Reserved. Atmel(R), logo and combinations thereof, AVR(R) and others, are registered trademarks, or trademarks of Atmel Corporation or its subsidiaries. Other terms and product names may be trademarks of others.
Information:
For further information on AVR32, go to http://www.atmel.com/avr32
Press Contacts:
Philippe Faure, Marketing Communications Director - Microcontrollers
Phone: +33 2 40 18 18 87, Email: philippe.faure@nto.atmel.com
Helen Perlegos, Public Relations - USA and Asia Pacific Rim
Phone: (+1) 408 487-2963, Email: hperlegos@atmel.com
Veronique Sablereau, Corporate Communications Manager - Europe
Phone: +33 1 30 60 70 68, Fax: + 49 71 31 67 24 23
Email: veronique.sablereau@atmel.com
SOURCE Atmel Corporation
----------------------------------------------
Philippe Faure
Marketing Communications Director
Microcontrollers
+33 2 40 18 18 87
philippe.faure@nto.atmel.com
or Helen Perlegos
Public Relations - USA and Asia Pacific Rim
+1-408-487-2963
hperlegos@atmel.com
or Veronique Sablereau
Corporate Communications Manager - Europe
+33 1 30 60 70 68
Fax: + 49 71 31 67 24 23
veronique.sablereau@atmel.com
all of Atmel Corporation
have fun!! :)
CAAS new high 7.59
6/20/2007 USBO 1-85 R/S ** US BioTec Inc Common Shares (NV) USBC US BioTec Inc New Common Shares (NV)
from the letter "The facts reflected on the price and volume attachment to this letter clearly establish
that resale of the more than 25,000,000 Nashville shares sold in reliance on Rule
504(b)(1)(iii) has had a profound detrimental effect on the market for Nashville
shares which is sufficient to create an overwhelming inference that Mazuma and
persons to whom it has distributed shares on the second level are effecting an
unregistered distribution of Nashville shares in violation of § 5 of the Securities Act
of 1933."
JAMES N. BARBER
Attorney at Law
Suite 10, Chase Tower
50 West Broadway
Salt Lake City, UT 84101
Telephone: (801) ***-****
Facsimile: (801) ***-**** E-Mail: ******************
May 30, 2007
Nashville Records, Inc.
1216 16th Avenue South
Nashville, TN 37212
Continental Stock Transfer
17 Battery Place
Eighth Floor
New York, NY 11520
Delivered by Fax: (212) 616-7609
Re: Shares issued in Rule 504 D transactions
Dear Interested Parties:
This letter is in response to information I received last Thursday and Friday related to the
sale and resale of shares offered, sold and delivered after sale by Nashville Records, Inc. without
registration under the Securities Act of 1933, as amended (the “Act”) in reliance on the
exemption from registration provided by §3(b) of the Act and Rule 504(b)(iii) of Regulation D
promulgated thereunder. This letter constitutes notice that on Friday, May 25, 2007 I advised
Nashville that it should immediately terminate this offering, take any available measures to
recover the shares sold, and prevent further sales of shares distributed on this offering into the
market because in my judgment, the exemption on which Nashville relied to sell these shares
without registration may not be available and because resale of the shares into the market by the
person who bought them directly from the issuer (and those to whom it has redistributed the
shares on the second level) very likely constitutes an unlawful distribution of shares in violation
of the Act.
The critical aspect of this offering is that whereas most shares distributed in reliance on
Rule 504 and the other rules encompassed in Regulation D are subject to the following provision
of Rule 502(d):
(d) Limitations on resale. Except as provided in §230.504(b)(1), securities acquired in
a transaction under Regulation D shall have the status of securities acquired in a
transaction under section 4(2) of the Act and cannot be resold without registration
under the Act or an exemption therefrom. The issuer shall exercise reasonable care to
Nashville Records, Inc.
Continental Stock Transfer
May 30, 2007
Page 2
assure that the purchasers of the securities are not underwriters within the meaning of
section 2(11) of the Act, which reasonable care may be demonstrated by the
following:
The rule goes on to list several steps the issuer can take to demonstrate that it has taken sufficient
measures to prevent unregistered secondary distribution of Regulation D shares. The exception
noted in Rule 502(d) is found in Rule 504(b)(1)(iii) which, insofar as it is relevant, contains this
provision:
(b) Conditions to be met – (1)General conditions. To qualify for exemption under this
§230.504, offers and sales must satisfy the terms and conditions of §230.501 and
§230.502 (a), (c) and (d), except that the provisions of §230.502 (c) and (d) will not apply
to offers and sales of securities under this §230.504 that are made:
(iii) Exclusively according to state law exemptions from registration that
permit general solicitation and general advertising so long as sales are made only
to “accredited investors” as defined in §230.501(a).
I am advised that the state law exemption from registration relied upon to exempt the shares
issued in this offering from the resale restrictions imposed by paragraph 502(d) was Section
80A.15(2)(g) of the Minnesota statutes of 2006 and Rule 2875.0170 adopted thereunder which
includes sales to accredited investors within the exemption provided by that section. Based on
reliance on the aforesaid Minnesota provisions, Nashville instructed its transfer to issue
certificates representing these shares to the purchasers without restrictive legends. While we are
concerned about all the shares issued in this offering, we are particularly concerned about the
following certificates.
Cert. No. Registered Owner No. Shares
50 Ameritrade _ T Violette 5,000,000
51 Perlinda (1) 5,000,000
4 TJ Management (1) 2,083,333
1 Mazuma Corporation 1,714,285
8 Mazuma Corporation 3,428,571
46 Mazuma Corporation 8,000,000
25,226,189
Numbered paragraph 6 of the Preliminary Notes to Regulation D reads as follows:
6. In view of the objectives of these rules and the policies underlying the Act,
regulation D is not available to any issuer for any transaction or chain of transactions
that, although in technical compliance with these rules, is part of a plan or scheme to
Nashville Records, Inc.
Continental Stock Transfer
May 30, 2007
Page 3
evade the registration provisions of the Act. In such cases, registration under the Act
is required.
It is my opinion that the exemption provided by Rule 504(b)(1)(iii) of regulation D under the
Act is not available to exempt the sale of the foregoing shares or any other shares on this
offering as free-trading common shares of Nashville Records, Inc. because the circumstances of
the offering establish that reliance on that exemption is nothing more than a device to avoid
registration of the shares under § 5 of the Act. Without limitation, the following facts support
this opinion.
1. While Mazuma Corp. is a Minnesota corporation in good standing, its business office
is listed as 7900 International Drive, Suite 200, Bloomington, MN 55425, a location
that features itself on the internet as the “Davinci Virtual Offices.” Literally hundreds
of businesses list this building as their address; and other evidence in my possession
establishes to my satisfaction that Mazumas address is nothing more than a mail drop
designed to create the illusion that Mazuma actually maintains a business presence in
Minnesota so as to avail itself of the 504(b)(iii) exemption. The evidence supports
the inference that this is a sham.
2. There is also an overwhelming inference that transactions in these “free-trading” 504
shares being effected by Mazuma corp. and persons to whom it has distributed
shares it purchased from Nashville under Rule 504(b)(iii) are constituting an
unregistered secondary “distribution” of Nashville shares which is sufficient to make
the sellers “underwriters” as that term is defined by § 2(11) of the Act and deprive
them of the right to rely on § 4(1) or any other exemption from registration to resell
the Nashville shares it purchased under Rule 504 without registration. That evidence
is derived in substantial measure form price and volume information that is publicly
available regarding Nashville common shares on the Pink Sheets market over the last
six weeks. Nashville received the first funds from this offering on April 12, 2007 and
it can be presumed that certificates representing the shares sold thereon reached the
registered owners approximately ten days later, i.e., approximately April 23, 2007.
On the latter date, the bid price of Nashville shares on the Pink Sheets was $.029 per
share. That price represents a drop of $.041 from the bid price of $.07 quoted on
April 12, 2007. That drop occurred over the ten days immediately after Mazuma as
assured it would be receiving large blocks of Nashville shares and raises a compelling
_________________________
47 FR 11262, Mar. 16,1982, as amended at 47 FR 54771, Dec. 6, 1982; 55 FR 18322,
May 2, 1990
Nashville Records, Inc.
Continental Stock Transfer
May 30, 2007
Page 4
inference that Mazuma may have been shorting stock against the position it had
purchased during that ten day period. The reported volume on April 12, 2007 was
45,300 shares and fluctuated between 25,200 and 800,241 shares until May 7. The
price stayed around $.025 per share during that period. During the next fifteen
trading days (until Nashville served notice that it intended to stop transfer of the
shares) the average trading volume increased to 2,406.836 shares per day and the
price dropped to $.014 on the date of this letter.
In the Preliminary Note to Rule 144 under the Act the Staff of the Securities and
Exchange Commission made the following comment regarding the definition if
“underwriter” and availability of § 4 (1) to cover unregistered sales of shares:
A third factor, which must be considered in determining what is
deemed not to constitute a “distribution, “ is the impact of the particular
transaction or transactions on the trading markets. Section 4(1) was
intended to exempt only routine trading transactions between individual
investors with respect to securities already issued and not to exempt
distributions by issuers or acts of other individuals who engage in steps
necessary to such distributions.. Therefore, a person reselling securities
under Section 4(1) of the Act must sell the securities in such limited
quantities and in such a manner as not to disrupt the trading markets.
The facts reflected on the price and volume attachment to this letter clearly establish
that resale of the more than 25,000,000 Nashville shares sold in reliance on Rule
504(b)(1)(iii) has had a profound detrimental effect on the market for Nashville
shares which is sufficient to create an overwhelming inference that Mazuma and
persons to whom it has distributed shares on the second level are effecting an
unregistered distribution of Nashville shares in violation of § 5 of the Securities Act
of 1933.
Based on the foregoing I support the actions of Nashville in placeing stop-transfer
instructions on the referenced shares with its transfer agent and advising Mazuma Corp. and all
persons to whom it has distributed shares it purchased from the issuer in reliance on Rule
504(b)(1)(iii) of the issuer’s opinion that resale of the shares is constituting an unregistered
distribution of Nashville shares in violation of § 2(11), § 4(10 and § 5 of the Securities Act of
1933. I have advised Nashville to retain counsel to file suit to enjoin further resales of these
shares, and to take all such other measures as may be available to limit the damage being inflicted
on other owners of Nashville Records, Inc. common stock by the conduct of the owners
Nashville Records, Inc.
Continental Stock Transfer
May 30, 2007
Page 5
of the shares referenced in this letter, as well as other shares sold in the subject offering.
I will be available to address any questions that may be raised about the legal conclusions
expressed in this letter or the factual predicates on which they are based.
Encl.
i believe the 504 was for 25M shares
NSHV .021 Nashville Records, Inc. Announces Rescission of Private Offering
Jun 19, 2007 9:27:00 AM
Copyright Business Wire 2007
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Nashville Records, Inc. (PINK SHEETS: NSHV) investor relations has recently received calls from investors regarding decline in share price and apparent shares sold onto the market. In response, the company has examined all possible selling sources and has identified a breach of contract regarding a previously arranged 504-D issuance of shares. All shares issued from this transaction have been recalled and "Stop Transfer" orders have been issued to the Company's transfer agent.
While the shares were legitimately owned by the 504-D purchaser, they were never intended to become free trading and Nashville Records(TM) engaged attorneys to deem the entire contract null and void, and force the return of all shares back to the company. 504-D shares not yet sold into the market are to be returned immediately to the company treasury - all sold shares will have to be re-purchased on the open market and returned to the company treasury.
Between April 12, 2007 and May 1, 2007 the company entered the 504-D offering encompassing two issuances of shares and one transaction that had not resulted in funds being received by the Company.
Upon further review by the Company's securities attorney, an opinion letter was issued and sent to the various parties involved, their legal counsels, and the brokers or market makers who seemed to be trading in the shares.
The offering itself, which was conducted as an exempt intra-state offering in the state of Minnesota, was credible and legally sufficient and was handled by specialized securities attorneys, but it was the opinion of Nashville Records and its securities counsel that the follow-up redistribution of the shares to holders in another State was an unregistered underwriting that not only violated the spirit of the exemption, but State and Federal Securities laws as well.
While the opinion of counsel letter is far too voluminous to publish via a press release, it can be viewed as text on the Company's website, http://www.nashvillerecords.com.
A Minnesota securities attorney will be retained to seek a permanent injunction to halt trading of the tainted shares, possibly with the aid of the Minnesota Securities Department.
Although the company regrets this issuance, it is acting aggressively to find a swift resolution. It is important to company management that transparency with shareholders is maintained regarding evolutionary steps in our development. While the company was founded on expert talent from the music industry, the unique risks associated with being traded on the public market will be minimized in the future by engagement of legal and investment banking advise before actions of this nature are undertaken.
The company's reaction to the contractual breach will eventually result in the forced buyback and return of 25,226,189 shares to the Company treasury. One purchaser in the 504-D offering has voluntarily returned 2,083,333 shares that have been cancelled. The Company assumes that a large portion of the remaining shares may have been sold into market.
Source: Nashville Records, Inc.
----------------------------------------------
Nashville Records
Inc.
David J. DiRicco
877-995-0992
Pink Sheets Accepts Citi as ADR Depositary PAL for International OTCQX Companies
Jun 19, 2007 9:27:00 AM
NEW YORK, NY -- (MARKETWIRE) -- 06/19/07 -- Pink Sheets, LLC today announced that Citi (NYSE: C) has been approved as an American Depositary Receipt (ADR) Principal American Liaison (PAL) for International OTCQX-listed companies. Citi may act as a PAL for its international exchange-listed clients that have a sponsored Level I ADR program in the U.S.
"We welcome Citi as an ADR Depositary PAL and are pleased that they will facilitate their clients' listings on International OTCQX," commented Cromwell Coulson, Chairman and CEO of Pink Sheets, LLC. "We look forward to improving the visibility of Citi's ADR programs by providing U.S. investors with transparent trading and easy access to disclosure through International OTCQX."
"We are pleased to be the depositary for International OTCQX programs, allowing issuers a wide range of DR instruments to choose from," said Nancy Lissemore, Managing Director of Depositary Receipt Services at Citi. "This alternative for Level I programs shows how DRs are a flexible instrument that can help an issuer broaden its visibility and reach among global investors."
International OTCQX is a new market tier offered by Pink Sheets that provides a premier trading, quotation and disclosure venue for securities of the highest quality international companies that trade in the U.S. OTC markets. Companies that are listed on a qualified international stock exchange are eligible to have their securities included in the premium tier International OTCQX, which commenced trading on March 5, 2007. International OTCQX allows non-U.S. issuers to use the SEC Rule 12g3-2(b) information supplying exemption from U.S. Securities and Exchange Commission reporting requirements and Sarbanes-Oxley Act compliance. International OTCQX-listed companies are instead required to post their home-country disclosure in English on the OTCQX website (www.otcqx.com) so that U.S investors can conveniently and efficiently access company disclosure.
About Citi
Citi, the leading global financial services company, has some 200 million customer accounts and does business in more than 100 countries, providing consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, and wealth management. Citi's brand names include Citibank, CitiFinancial, Primerica, Citi Smith Barney and Banamex. Additional information may be found at www.citigroup.com or www.citi.com.
About Pink Sheets, LLC
Pink Sheets, LLC is the leading provider of pricing and financial information for the over-the-counter (OTC) securities markets. Its centralized information network includes services designed to benefit market makers, issuers, brokers and OTC investors. Pink Sheets information enhances the efficiency of OTC trading, provides better executions for OTC investors and improves the capital formation process for OTC issuers. For more information, visit the Pink Sheets website at www.pinksheets.com.
Contact:
Pink Sheets, LLC
1 (212) 896-4420
Email Contact
CRGI 5.17 Corgi International & Exodus Film Group Announce Master Toy License for CG-Animated Film ''Igor''
Jun 19, 2007 9:16:00 AM
Copyright Business Wire 2007
LOS ANGELES--(BUSINESS WIRE)--
Exodus Film Group and Corgi International Limited (NASDAQ GM:CRGI) announced today a master license for a product line of toys and collectibles for Exodus' CG-animated feature film "Igor." The Weinstein Company is handling worldwide distribution for the film, which is set for a wide theatrical release on October 24, 2008.
This worldwide agreement will allow Corgi International to release a wide range of products including action figures, play sets, electronic role-play games, pocket money toys, vinyl figures, plush, statues, busts and other associated products.
Corgi International CEO Michael Cookson commented, "We have been discussing the opportunities that surrounded this spectacular project from the very early stages and are excited to bring to market a wonderful line of products for 'Igor' which will cross all boundaries of the marketplace and be the start of a superb licensing franchise for Exodus. Our innovative and unique products will be released September 2008 and we are confident that our worldwide core customer base will get behind the terrific range of products for this much anticipated film."
Bruce Auerbach, Exodus President of Consumer Products, added, "Corgi International is a worldwide leader in the toy and collectable arena with licenses to some of the highest grossing film franchises of all time. We couldn't ask for a better master toy partner and are thrilled to be working with them."
"Igor" is a playfully irreverent comedy that brings a new twist to the classic monster genre. In a world filled with Mad Scientists and Evil Inventions, one talented evil scientist's hunch-backed lab assistant has big dreams of becoming a Mad Scientist himself and winning the annual Evil Science Fair. The stellar voice cast includes Steve Buscemi, John Cleese, Jennifer Coolidge, John Cusack, Arsenio Hall, Sean Hayes, Jay Leno, Molly Shannon, Jeremy Piven and Christian Slater. Award-winning animation writer, Tony Leondis, is directing the screenplay by Chris McKenna. Exodus CEO John D. Eraklis is producing with Exodus President Max Howard executive producing and Jean-Luc De Fanti producing on behalf of Exodus Productions in Paris. Eric Robinson, Vice President of Production and Development, is overseeing on behalf of The Weinstein Company.
Award-winning global leader Simon & Schuster Children's Publishing Division announced a major publishing deal last month for seven "Igor" books which will be published under their Simon Scribbles and Simon Spotlight imprints.
ABOUT EXODUS FILM GROUP
Exodus Film Group is an independent production company which has taken pioneering steps in the animation field by creating one of the first private equity animation film funds. Exodus announced at last month's Cannes Film Festival a strategic alliance with The Weinstein Company to jointly develop, produce and finance a multi-picture slate of CG-animated feature films, DVDs, and television series, with TWC distributing worldwide. Los Angeles, California-based Exodus recently opened an additional office in New York City and has its European operations based in Paris, France. In addition to "Igor," Exodus' CG-animation slate includes "Bunyan & Babe" and "The Hero of Color City," which is in pre- production and will be distributed in North America by Magnolia Pictures.
ABOUT CORGI INTERNATIONAL
Corgi International develops and markets innovative, high-quality licensed and unlicensed pop culture collectibles, gifts and toys ranging from high-end movie and television prop replicas to lower price-point gifts and toys. The company holds licenses for pop culture collectibles, gifts and toys for many of the highest grossing film franchises of all time including "Batman," "Disney Classics," "Harry Potter," "James Bond," "Pirates of the Caribbean," "Star Trek," "Spiderman 3," and "Star Wars." The company is headquartered in Hong Kong, with offices in Walnut Creek, CA, Chicago, IL, and the United Kingdom.
Source: Exodus Film Group
----------------------------------------------
EXODUS FILM GROUP
Media Relations:
Spence Bovee
310-392-7778
Spence@ExodusFilmGroup.com
or
CORGI INTERNATIONAL LIMITED
Investor Relations:
The BlueShirt Group
Peter Ausnit
415-217-5863
Peter@BlueShirtGroup.com
RDTA 3.10 Raining Data Announces Major New 3.0 Release of TigerLogic XML Data Management Server
Jun 19, 2007 9:15:00 AM
IRVINE, Calif., June 19 /PRNewswire-FirstCall/ --
-- High Performance Native XML Data Management Server with Self-Defining
Data Structure
-- XA Transaction Compliant with Enhanced Node Level Update and Locking
-- Cache Adapter Provides Cached Views, with Refresh Policies, from any
Data Source
-- Supports up to 64 GB of In-Memory Cache from any Data Source
-- Native Geospatial Support of XML Messages
Raining Data Corporation (Nasdaq: RDTA), a long-time provider of scalable, flexible and reliable data management software, today announced the beta availability of its new 3.0 release of TigerLogic(R) XML Data Management Server (XDMS) software, which supports the January 2007 W3C XML Query 1.0 specification. TigerLogic XDMS includes the TigerLogic high performance native XML database and TigerLogic XQuery engine. Unlike a relational database, the TigerLogic XML database handles multiple XML structures in the same collection and automatically evolves the structure as new data is introduced, providing excellent interoperability capabilities for dynamic data sources. TigerLogic XDMS provides full XA transaction compliance (two-phase commit) with true node level update and locking.
TigerLogic XDMS 3.0 introduces the new cache adapter, which provides cached views from any data source, including Web Services, with refresh policies, exposing defined views of data for specific application requirements and off-loading the need to always query the back-end data source. Users can also configure up to 64 GB of in-memory cache, for accelerated query performance. TigerLogic XDMS 3.0 supports the Geographic Markup Language (GML) to model geospatial data in XML and uses GiST-based spatial indexing for consolidated and efficient search. In addition to the existing TigerLogic XDMS APIs, TigerLogic XDMS 3.0 now supports new client APIs: XQJ (JSR 225 - XQuery API for Java), ADO.NET (native .NET support) and an embedded HTTP server supporting native Web Services (for ease of deployment of any XQuery as a Web Service). For enhanced reliability, TigerLogic XDMS introduces replication (which supports up to eight replicated subscriber nodes from a single publisher node) and a two-node High-Availability cluster for failover.
After performing an extensive evaluation of database vendors, Nextrials, an Electronic Data Capture software company for clinical trials in the life science industry, selected TigerLogic XDMS 3.0. According to Bob Lyons, Chief Technology Officer of Nextrials, "If you spend 90% of your time dealing with XML format, reading it, rendering it, etc., then why fight and store your data in some other representation? We needed to manage large XML documents and only TigerLogic provided high performance XML data management with two-phase commit transactional compliance and true node level locking for concurrent updates. Additionally, we can now store an entire clinical trial study in-memory for even greater performance."
Cache Adapter
There is a need in many large organizations to bring together data from disparate data sources and make it available to data consumers. Mid-tier cache enables performance acceleration and mitigates contention on back-end systems. The TigerLogic XDMS cache adapter provides the ability to automatically cache any data addressable by the TigerLogic XDMS, including the native XML database, relational databases, Web Services, file systems, FTP, HTTP, etc. The cache adapter provides policy-driven read and write access to the data to ensure that the cached data is in-synch with the source data. With TigerLogic XDMS multi-schema engine and schema evolution, the cache adapter also handles dynamic data sources.
In Memory Cache
For additional performance, TigerLogic XDMS supports up to 64 GB of dedicated in-memory cache that is user configurable. The in-memory cache can be utilized to store data from the TigerLogic XDMS native XML database (both native and cached collections) in-memory for accelerated performance of queries.
Geospatial
High volume geospatial data in XML messages are becoming more prevalent in government and commercial applications such as those providing services to mobile wireless devices. TigerLogic XDMS provides an efficient and low cost method to handle this data by using commodity hardware, keeping data in an XML format and utilizing the in-memory cache. TigerLogic XDMS 3.0 includes a geospatial XQuery plug-in that employs GML to model geospatial data in XML. It is based on Open Geospatial Consortium Simple Features specification. Geospatial indexing is based on GiST and all supported GML constructs in the collection are automatically indexed.
Availability
Raining Data's TigerLogic XDMS version 3.0 is currently available in beta. The future General Availability (GA) version will support Windows, Linux and Solaris platforms. To learn more about TigerLogic XDMS, go to http://www.rainingdata.com/products/tl/index.html.
Raining Data offers a Free Trial Version of TigerLogic XDMS. To download an evaluation copy, please register at http://www.rainingdata.com/products/tl1/signup1/index.html.
About Raining Data
Raining Data Corporation (Nasdaq: RDTA) has been providing reliable data management solutions for more than three decades. Product offerings include the high performance TigerLogic(R) XML Data Management Server, Pick(R) Universal Data Model based data management systems, .NET integration solutions and TigerLogic(R) XML Workflow Management Server. Solution offerings include TigerLogic Staging Server and Data Governance as well as vertical solutions in Life Sciences. Raining Data's customers represent more than 500,000 active users across 20,000 customer sites worldwide in a diverse set of vertical applications. More information about Raining Data Corporation and its products can be found at http://www.rainingdata.com.
SOURCE Raining Data Corporation
----------------------------------------------
Bob Albo
Vice President of Business Solutions
+1-408-236-7619
fax
+1-949-250-8187
bob.albo@rainingdata.com
for Raining Data Corporation
TSN All Tyson Brand Fresh Chicken to be 'Raised Without Antibiotics'
Products Available to Mainstream Consumers At An Affordable Price
Jun 19, 2007 9:15:00 AM
2007 PrimeNewswire, Inc.
NEW YORK, June 19, 2007 (PRIME NEWSWIRE) -- In response to broadscale consumer demand, Tyson Foods, Inc. (NYSE:TSN) is now producing all of its Tyson(r) brand fresh chicken from birds "Raised Without Antibiotics", the company will announce at a news conference here today.
"While we have great confidence in the quality of our traditional chicken, we're also committed to providing mainstream consumers with the kind of products they want," said Richard L. Bond, president and CEO of Tyson Foods.
"According to our research, 91% of consumers agree it's important to have fresh chicken produced and labeled 'raised without antibiotics'," Bond said.
Tyson started selling 100% All Natural(tm), Raised Without Antibiotics chicken this week. The product is being distributed nationwide in newly-designed packaging highlighting that the chicken is raised without antibiotics and contains no artificial ingredients. Several of the skinless breast meat products also meet the heart-healthy food criteria of the American Heart Association.
"This is great news for American consumers who have made it clear they pay attention to the use and presence of all sorts of antibiotics in the environment," said Dr. Lisa Hark, PhD, RD, director of the Nutrition Education Program at the University of Pennsylvania School of Medicine. "Now families can buy fresh chicken raised without antibiotics at their regular grocery store without a trip to an expensive specialty store. And because Tyson is available across the country, this is news every family will care about."
Company officials expect to convert Tyson Deli Rotisserie and Marinated Raw Breaded eight-piece items to Raised Without Antibiotics starting in early July and Tyson retail individually quick frozen chicken by late-August.
"We are the first major poultry company to offer fresh chicken raised without antibiotics on a large scale basis and at an affordable price for mainstream consumers," said Dave Hogberg, senior vice president - Fresh Meal Solutions for Tyson. "Because of the size and scale of our operations, we're able to convert our entire branded business and assure supply to our customers."
Although chicken Raised Without Antibiotics will cost more, Tyson's market research shows the higher price is well below the additional cost consumers say they are willing to pay for such products. It also will be substantially less than the premium currently charged by most competing niche brands.
Tyson uses therapeutic antibiotics in only a very small percentage of its poultry flocks and only to treat or prevent disease. As part of the company's commitment to animal well-being, Tyson will continue to use antibiotics on its birds when necessary and only for therapeutic reasons. Products from treated flocks will continue to be produced to the most stringent Tyson quality standards, but will not be included under the new Raised Without Antibiotics label.
Tyson will promote 100% All Natural(tm), Raised Without Antibiotics chicken as part of the company's new marketing campaign. The $70 million advertising and promotion plan is titled "Thank You" and will convey how Tyson products help make Mom a hero at mealtime. The marketing plan includes TV and radio advertising, plus strong consumer promotions to drive new and repeat purchases.
The initiative is another example of Tyson's strategy of offering meaningful benefits to consumers that are focused on health, wellness and convenience. Tyson led the poultry industry in 2004 by becoming one of the first companies to begin removing added trans fats from its breaded poultry products. In 2006, Tyson converted its marinated fresh chicken to 100% All Natural(tm), which means it is minimally processed and has no artificial ingredients.
Tyson Foods will hold a news conference today at 10 a.m. Eastern to discuss the company's move to Raised Without Antibiotics fresh chicken. To access a webcast of the news conference, go to http://tysonwebcast.onthescene.com/. Reporters listening to the webcast may submit questions before and during the conference by sending an e-mail to: TysonQuestions@onthescene.com.
Tyson Foods, Inc. (NYSE:TSN), founded in 1935 with headquarters in Springdale, Arkansas, is the world's largest processor and marketer of chicken, beef, and pork, the second-largest food production company in the Fortune 500 and a member of the S&P 500. The company produces a wide variety of protein-based and prepared food products and is the recognized market leader in the retail and foodservice markets it serves. Tyson provides products and service to customers throughout the United States and more than 80 countries. The company has approximately 107,000 Team Members employed at more than 300 facilities and offices in the United States and around the world. Through its Core Values, Code of Conduct and Team Member Bill of Rights, Tyson strives to operate with integrity and trust and is committed to creating value for its shareholders, customers and Team Members. The company also strives to be faith-friendly, provide a safe work environment and serve as stewards of the animals, land and environment entrusted to it.
The Tyson Foods, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3224
CONTACT: Tyson Foods, Inc.
Gary Mickelson
479-290-6111
gary.mickelson@tyson.com
SOFO 2.32 Sonic Foundry Highlights Enterprise Applications of Mediasite at InfoComm and EduComm 2007
Company is EduComm platinum sponsor and will provide event webcasting services
Jun 19, 2007 9:00:00 AM
ANAHEIM, Calif., June 19 /PRNewswire-FirstCall/ -- (InfoComm booth #2233, EduComm booth #3626) --Sonic Foundry(R) Inc. (Nasdaq: SOFO), a leader in automated rich media communications technology, today announced it will be participating in InfoComm and EduComm 2007 taking place at the Anaheim Convention Center and Anaheim Marriott Hotel from June 19 - 21.
Sonic Foundry is a platinum sponsor of EduComm 2007 and has been selected as the conference's webcasting platform for the event. Two presentations by Sonic Foundry and Clemson University will feature Mediasite best practices and university enterprise applications. "Enhancing Student Learning with Webcasting" by Clemson University's William Havice, PhD, Professor and Associate Dean, and Pamela Havice, PhD, College of Health, Education and Human Development, will take place Tuesday, June 19, at 4:15 in Anaheim Marriott Grand Ballroom Salon G-K. Sonic Foundry's vice president of education Sean Brown will present "Emerging Trends in Classroom Webcasting" on Thursday, June 21, at 10:00 in Anaheim Marriott Grand Ballroom Salon A-D.
The company will showcase automated scheduling capabilities for its patented Mediasite(R) family of web communication solutions. For enterprise customers who create large libraries of recurring presentations, this latest release provides for automated scheduling of presentation recordings featuring the industry's first flexible start-stop functionality. Coupled with Mediasite Podcast, which automatically transforms any Mediasite presentation into portable audio content for on-the-go playback with Apple(R) iPods(R), iTunes(R) or any other MP3 player, these Mediasite capabilities streamline recording while distributing the content in multiple formats for today's media-savvy students and mobile workforce.
"We have specifically designed Mediasite Recorders and EX Server software for technology-enhanced learning in large-scale deployments across the university enterprise," said Rimas Buinevicius, chairman and CEO of Sonic Foundry. "These latest enhancements represent the industry's most advanced methods for the automated capture, management, delivery and search of in-class teaching for blended and distributed learning."
About Sonic Foundry(R), Inc.
Founded in 1991, Sonic Foundry (Nasdaq: SOFO) is a technology leader in the emerging rich media communications marketplace, providing enterprise solutions and services that link an information-driven world. Sonic Foundry is changing the way organizations communicate via the web and how people around the globe receive vital information needed for work, professional advancement, safety and education. The company's integrated webcasting and web presentation solutions are trusted by Fortune 500 companies, education institutions and government agencies for a variety of critical communication needs. Sonic Foundry is based in Madison, Wis. For more information about Sonic Foundry, visit http://www.sonicfoundry.com.
Certain statements contained in this news release regarding matters that are not historical facts may be forward-looking statements. Because such forward-looking statements include risks and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties pertaining to continued market acceptance for Sonic Foundry's products, its ability to succeed in capturing significant revenues from media services and/or systems, the effect of new competitors in its market and other risk factors identified from time to time in its filings with the Securities and Exchange Commission.
SOURCE Sonic Foundry, Inc.
----------------------------------------------
Erica St. Angel of Sonic Foundry
+1-608-443-1600
ericas@sonicfoundry.com
UTSI 5.53 UTStarcom Delivers Video Mail With Implicity(TM)
New Platform Expands on UTStarcom's Field-Proven, All-IP Messaging Solution
Jun 19, 2007 9:00:00 AM
CHICAGO, June 19 /PRNewswire-FirstCall/ -- NXTCOMM -- UTStarcom, Inc. (Nasdaq: UTSI), a global leader in IP-based, end-to-end networking solutions and services, today introduced its Implicity(TM) platform into the company's converged IP Messaging solution portfolio. Implicity will make its debut at UTStarcom Booth #4068 at NXTCOMM, June 18-21, in Chicago.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051013/SFTH063LOGO)
The Implicity platform continues to offer many of the IP messaging and service delivery benefits available with UTStarcom's first-generation Personal Communications Management System (PCMS) platform, but has been enhanced to include many new and exciting features such as multimedia and video mail capabilities.
"The debut of Implicity demonstrates UTStarcom's commitment to providing carriers with the evolution path towards IMS," said David King, senior vice president of international sales and marketing at UTStarcom, Inc. "This platform enables us to now offer operators a cost-effective approach to their IMS deployments around the world by delivering an intriguing new, interactive messaging experience to their customers."
Enhanced and Distributed Network Architecture
Implicity is an enhanced IP messaging platform that supports many network architecture designs, including those used by wireless and broadband subscribers. This SIP-based system provides carrier-class system reliability on agnostic, non-proprietary technology, and it does not require any complex, underlying specialized hardware - making it easy to customize.
Scalable and Flexible Platform
UTStarcom's Implicity platform maintains the bandwidth parameters to handle millions of subscribers at entry-level cost performance, and it has the capability of supporting a Centrex/wholesale model. This new IP platform also supports an intuitive service creation environment that houses an emergency notification application, location-based services and additional products.
With UTStarcom's Implicity, carriers can provide converged, rich revenue- generating services, including video e-mail, instant messaging, standard e- mail, voicemail and conferencing through an IMS-enabling architecture. The interoperability capabilities of this platform also will enable residential, mobile and business-centric users to communicate with and gain immediate access to voice and data messages stored on any of their other handheld devices - from equipped cell phones to PDAs, smartphones and SIP phones.
"UTStarcom's new Implicity platform truly offers the next generation of IP messaging and data transfer," said Brian Caskey, vice president of worldwide marketing for UTStarcom, Inc. "As the industry is evolving, UTStarcom will continue to stay ahead of the curve by working with our clients - and their end users - to develop and deploy the technologies that will enable them to stay competitive in the marketplace."
About UTStarcom, Inc.
UTStarcom is a global leader in IP-based, end-to-end networking solutions and international service and support. The company sells its broadband, wireless, and handset solutions to operators in both emerging and established telecommunications markets around the world. UTStarcom enables its customers to rapidly deploy revenue-generating access services using their existing infrastructure, while providing a migration path to cost-efficient, end-to-end IP networks. Founded in 1991 and headquartered in Alameda, California, the company has research and design operations in the United States, Canada, China, Korea and India. UTStarcom is a FORTUNE 1000 company.
For more information about UTStarcom, visit the company's Web site at http://www.utstar.com.
SOURCE UTStarcom, Inc.
----------------------------------------------
Andy Tennille
Senior Manager
Public Relations of UTStarcom
Inc. +1-510-814-4421
andy.tennille@utstar.com; or Joseph Agbasi
Account Executive of Edelman
+1-404-262-3000
Joseph.agbasi@edelman.com
for UTStarcom
Inc.
DCGN 3.83 deCODE genetics to Webcast Presentations at its Annual R&D Event
Jun 19, 2007 8:47:00 AM
REYKJAVIK, Iceland, June 19 /PRNewswire-FirstCall/ -. deCODE genetics (Nasdaq: DCGN) today announced that it will webcast live the presentations at the company's annual R&D event being held in Reykjavik on Monday, June 25, 2007. deCODE management will present overviews of progress in the company's drug development, drug discovery, diagnostics and gene discovery programs, as well as updates on finance, intellectual property and corporate alliances. The program will begin at 9am GMT/5am Eastern Time, and is expected to last approximately four hours.
The webcast can be accessed through the Investors page on deCODE's website, http://www.decode.com. Those interested in listening should log on a few minutes in advance in order to download any software or complete any sign- in that may be required. The presentations will be archived on deCODE's website and the archived version will be made available shortly after the conclusion of the event.
About deCODE
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Contact:
deCODE genetics
Stefan Arnason
+354 570 1995
ir@decode.is
SOURCE deCODE genetics
----------------------------------------------
Stefan Arnason of deCODE genetics
+354-570-1995
ir@decode.is
JAV 6.65 Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
Rylomine(TM) Meets Primary Endpoint, Significantly Reduces Postsurgical Orthopedic Pain
Jun 19, 2007 8:40:00 AM
Copyright Business Wire 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Javelin Pharmaceuticals (AMEX: JAV) announced today that its product candidate Rylomine(TM) (intranasal morphine) successfully met its primary clinical endpoint, the Sum of the Pain Intensity Difference (SPID) scores over 0-24 hours postoperatively. In this first of two pivotal Phase 3 studies, patients with moderate-to-severe pain after elective orthopedic surgery were given 7.5 mg Rylomine every hour as needed, 15 mg Rylomine every 3 hours as needed, or 7.5 mg intravenous (IV) morphine every 3 hours as needed. Patients in each of the three active treatment groups had significantly better (p less than .01 or less) SPID scores over 24 hours than the corresponding placebo groups.
"Parenteral morphine is the gold standard for postoperative analgesia," commented Dr. Daniel B. Carr, CEO and CMO of Javelin Pharmaceuticals. "Today's gratifying results extend our prior positive study findings showing that Rylomine is a simple, effective alternative to more complex, cumbersome and costly methods of postoperative opioid analgesia. We look forward to continuing the development of this innovative product candidate."
There were no serious adverse events related to the study drug. Local adverse events associated with nasal administration (bad taste, throat irritation, instillation site reaction, nasal erythema, nasal irritation) were more common with Rylomine or intranasal placebo than the intravenous morphine groups. General systemic adverse events related to active drug were similar across morphine treatment groups regardless of route of administration and consistent with morphine's known pharmacologic effects (dizziness, nausea, transient decreased oxygen saturation, and vomiting).
Full analyses of the data are ongoing and will be reported when available.
About the Study
This study, termed MOR-003, involved 278 randomized patients with moderate to severe post-surgical pain enrolled at 7 sites in the United States. These patients received either 7.5 mg Rylomine every hour as needed, 15 mg Rylomine every three hours as needed, 7.5 mg IV morphine, or matching placebos. In this "blinded" study, patients received treatments of which the identity (active or placebo) was not known by either the Investigator or the patient, although patients did know whether they were receiving intravenous or intranasal treatment.
About Rylomine(TM)
Rylomine is a patient-controlled nasal spray that delivers a single metered dose of morphine, an opioid analgesic used for the treatment of moderate-to-severe pain. After use, a negligible amount of morphine remains in the dispenser, reducing the risk of scavenging and abuse of discarded devices. Data from clinical studies have demonstrated that Rylomine has similar efficacy to an infusion of intravenous morphine.
Parenteral morphine is the standard of care for management of acute moderate-to-severe pain, especially after surgery, when analgesic requirements vary between individuals and often fluctuate even in the same patient. IV morphine analgesia has rapid onset, proven efficacy, can accommodate variations in analgesic demand, and has side effects that are well understood by medical personnel. Morphine, like many drugs, is poorly absorbed across mucosal barriers and, in particular, the nasal membrane. Javelin's proprietary technology allows for nasal delivery of predictable therapeutic blood levels of morphine. The key to this technology is ChiSys(TM), a carbohydrate polymer that, while pharmaceutically inert by itself, enhances the absorption of compounds across mucosal membranes, such as in the nasal cavity. The contribution of ChiSys(TM) to enhancing mucosal drug absorption reflects several factors including its potent mucoadhesive property, which prevents drug washout. Rylomine is a novel formulation of morphine and ChiSys(TM) packaged in a single unit-dose nasal spray. Worldwide, no comparable formulation of morphine is available.
About Javelin Pharmaceuticals, Inc.
With US corporate headquarters in Cambridge, MA, and a European office in Cambridge, UK, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit www.javelinpharmaceuticals.com.
Forward-looking Statement
This press release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA (and foreign equivalent) review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.
JAV-G
Source: Javelin Pharmaceuticals, Inc.
----------------------------------------------
Javelin Pharmaceuticals
Inc.
Investor Relations & Media
Rick Pierce
617-349-4500
VP Investor Relations
rpierce@javelinpharmaceuticals.com
or
Corporate Communications
June Gregg
617-349-4500
jgregg@javelinpharmaceuticals.com
Fax: 617-349-4505
SUNW 5.03 Benchmark Results for Sun Fire X4600 Server Running Solaris 10 Demonstrate Industry-Best Speed and Reliability in Processing Heavy Market Data Workload
Jun 19, 2007 8:35:00 AM
NEW YORK, Securities Industry and Financial Markets Associate Conference (SIFMA), June 19 /PRNewswire-FirstCall/ -- Sun Microsystems, Inc. (Nasdaq: SUNW) today announced new benchmark performance results from its Sun Fire (TM) x4600 server, the industry's only 8-socket x86-based server from a tier-one server vendor. The Securities Technology Analysis Center (STAC) benchmark test measured the performance of the Sun Fire x4600 servers running Wombat Financial software on the Solaris(TM) 10 Operating System (OS). Handling the heaviest possible data load a client site could demand, the server achieved an exceptionally rapid processing speed - processing 359,000 messages per second, while reducing latency to just 511 µsec.
Millions of trades per second are communicated electronically by trading communities around the world. Just one millisecond of network delay can determine whether an order is successfully filled, making a server's processing speed and reliability a critical component of a capital markets firm's competitive edge. The results of the benchmark demonstrate that the Sun Fire x4600 series is excellently equipped to help capital markets firms compete on transaction speed and reliability.
The benchmark tested the capacity of the 8-socket Sun Fire x4600 server to handle the industry's heaviest market data workload through the Wombat Market Data Platform under two distribution scenarios from the Options Price Reporting Authority (OPRA). OPRA data rates are the most challenging in the industry, and the most likely to lead to server sprawl in customer data centers. During testing, the Sun Fire x4600 server running the Solaris 10 OS delivered an impressive per-server Wombat throughput of OPRA data with 359,000 updates per second. At this rate, two x4600 servers at full utilization could accommodate OPRA's total capacity upgrade in January 2008. Wombat's software was selected for the benchmark because it is generally regarded as the fastest and widely used market data platform in the algorithmic trading market.
The system tested featured Wombat Financial Software's feed handlers and new MAMA 4 market data platform API over 29West's Latency Busters Messaging (LBM) middleware. The servers were running the latest Solaris 10 11/06 OS release and contained dual core AMD Opteron (R) 2.8 GHZ processors. The test harness replayed recorded OPRA data at controlled rates and used standard Wombat test tools and procedures.
More information on this benchmark test can be found at http://www.stacresearch.com/index.php?option=com_content&task=view&id=43&Itemi d=33 .
About Sun Microsystems, Inc.
A singular vision -- "The Network Is The Computer" -- guides Sun in the development of technologies that power the world's most important markets. Sun's philosophy of sharing innovation and building communities is at the forefront of the next wave of computing: the Participation Age. Sun can be found in more than 100 countries and on the Web at http://sun.com.
Sun, Sun Microsystems, the Sun logo, and Sun Fire and The Network Is The Computer are trademarks of Sun Microsystems Inc. in the United States and other countries. AMD, Opteron, the AMD logo, the AMD Opteron logo are trademarks or registered trademarks of Advanced Micro Devices. Wombat and MAMA are trademarks of Wombat Financial Software Inc.
FOR MORE INFORMATION:
Elissa Ehrlich
Bite Communications for Sun Microsystems, Inc.
Phone: 212-857-9397
Mobile: 646-228-8960
elissa.ehrlich@bitepr.com
SOURCE Sun Microsystems, Inc.
----------------------------------------------
Elissa Ehrlich of Bite Communications
+1-212-857-9397
cell +1-646-228-8960
elissa.ehrlich@bitepr.com
for Sun Microsystems
Inc.
ABPI 3.21 Accentia Biopharmaceuticals, Inc. to Present at the Jefferies Healthcare Conference in New York City on June 27, 2007 at 9:40AM/ET
Jun 19, 2007 8:32:00 AM
Copyright Business Wire 2007
NEW YORK--(BUSINESS WIRE)--
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) will present at the Jefferies Healthcare Conference in New York City on June 27 at 9:40 AM/ET. Dr. Frank E. O'Donnell Jr., Accentia Biopharmaceutical's Chairman and Chief Executive Officer, will update attendees on the Company's ongoing Fast Tracked Phase 3 Clinical trial for SinuNase, which is in development to treat Chronic Sinusitis, BiovaxID, a Fast Tracked anti-cancer vaccine in Phase 3 clinical development for Non-Hodgkins Lymphoma, and Revimmune, a recently licensed therapeutic in development that the Company will enter into a Phase 3 clinical trial with a lead indication for Multiple Sclerosis.
Members of the investment community, the media, and other interested parties can access a live audio webcast of Accentia's presentation by visiting http://www.wsw.com/webcast/jeff18/abpi. The presentation will be available and archived for 90 days.
The conference will be held Tuesday, June 26 through Thursday, June 28, 2007. The three-day conference will showcase a diverse group of companies and industry experts in the areas of biotechnology, CROs, healthcare services, healthcare IT services, managed care, medical devices & diagnostics, and specialty pharmaceuticals. The conference will be organized by sector focus and will include public and private company presentations, panel discussions and investor meetings. To obtain additional information about the conference, please visit http://www.jefferies.com/0607hc.
About Accentia Biopharmaceuticals
Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company" or "Accentia") is a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities. The Company's lead product candidate is SinuNase(TM), a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. SinuNase has been granted Fast Track status by the FDA and it is currently in a pivotal Phase 3 clinical trial. During this fiscal year, the Company also plans to file an Investigative New Drug (IND) for a pivotal Phase 3 clinical trial of Revimmune, to treat numerous autoimmune diseases with an initial indication targeting refractory relapsing-remitting Multiple Sclerosis. Revimmune is based on pulsed, ultra-high dosing of a well-known chemotherapeutic agent under a risk management program. Additionally, through an investment strategy, the Company has acquired the majority ownership interest in Biovest International, Inc. ("Biovest"), (BVTI.OB) and a royalty interest in Biovest's lead drug candidate, BiovaxID(TM) and any other biologic products developed by Biovest. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. In addition to these product candidates, the Company has a specialty pharmaceutical business which markets products focused on respiratory disease and an analytical consulting business that serves customers in the biopharmaceutical industry. For further information, visit the Company Web site at www.accentia.net.
Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Revimmune(TM) SinuNase(TM), BiovaxID(TM), AutovaxID(TM), CRSFungal Profile(TM) and any other statements relating to products, product candidates, product development programs the FDA or clinical study process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Accentia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Source: Accentia Biopharmaceuticals, Inc.
----------------------------------------------
Accentia Biopharmaceuticals
Inc.
Tampa
FL
Susan Bonitz
Ph.D.
813-864-2554-Extension 277
sbonitz@accentia.net
or
The Investor Relations Group
New York
Investors:
Adam S. Holdsworth
212-825-3210
or
Media:
Janet Vasquez
212-825-3210
SONS 8.89 Independent Research Report Names Sonus Networks as the Leader Worldwide in High-Growth Areas of Next Generation Communications Industry
Jun 19, 2007 8:30:00 AM
WESTFORD, Mass. and CHICAGO, June 19 /PRNewswire-FirstCall/ -- NXTcomm 2007 -- Sonus Networks, Inc. (Nasdaq: SONS), a leading supplier of service provider Voice over IP (VoIP) infrastructure solutions, announced today at NXTcomm 2007 (Booth#4215), one of North America's largest communications industry trade shows, that according to independent research by Synergy Research Group, Sonus has once again achieved market share leadership in key segments of the next generation IP voice market for Q1 2007.
In Q1 2007, Sonus Networks led the worldwide high density VoIP gateway market with 31.6% market share. In the United States, Sonus led both the total gateway, with approximately 33%, and high density gateway with approximately, 42% markets. Sonus continues to garner a strong market share position in Japan, where Sonus is reported as achieving approximately 50% of the total gateway market and a dominating approximately 67% market share for high density gateways, more than 7x its closest competitor.
"Sonus has established itself as a leader on a global scale, ranking #1 in the US and Japan, and is rapidly establishing leadership in the growing European market," said Jeremy Duke, president and CEO, Synergy Research Group. "Sonus' ability to win network deployments with tier one operators globally, coupled with ramping traffic across its customer base has solidified Sonus' position as one of the premium providers of IP based voice equipment."
"Sonus has been selected by all five of the world's largest network operators and is expanding its presence with other leading operators around the world," said Hassan Ahmed, chairman and CEO, Sonus Networks. "Our ability to deliver networks with unparalleled quality, reliability, and scalability that are secure has enabled us to earn and maintain this coveted position as the #1 provider in key segments of the IP voice industry."
About Sonus Networks
Sonus Networks, Inc. is a leading provider of voice over IP (VoIP) infrastructure solutions for wireline and wireless service providers. With its comprehensive IP Multimedia Subsystem (IMS) solution, Sonus addresses the full range of carrier applications, including residential and business voice services, wireless voice and multimedia, trunking and tandem switching, carrier interconnection and enhanced services. Sonus' voice infrastructure solutions are deployed in service provider networks worldwide. Founded in 1997, Sonus is headquartered in Westford, Massachusetts. Additional information on Sonus is available at http://www.sonusnet.com.
This release may contain forward-looking statements regarding future events that involve risks and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results. Readers are referred to Item 1A "Risk Factors" of Sonus' Quarterly Report on Form 10-Q dated May 8, 2006, filed with the SEC, which identifies important risk factors that could cause actual results to differ from those contained in the forward-looking statements. Risk factors include among others: the impact of material weaknesses in our disclosure controls and procedures and our internal control over financial reporting on our ability to report our financial results timely and accurately; the unpredictability of our quarterly financial results; risks and uncertainties associated with the Company's announced review of its historical stock option grants and accounting, including the impact on the Company's financial statements or results, any tax liabilities or penalties, the Company's inability to timely report with the Securities and Exchange Commission, whether the Company will file its required SEC reports by June 26, 2007 and remain listed on the NASDAQ Global Select Market, regulatory actions or litigation arising out of the review or any restatement; risks associated with our international expansion and growth; consolidation in the telecommunications industry; and potential costs resulting from pending securities litigation against the company. Any forward-looking statements represent Sonus' views only as of today and should not be relied upon as representing Sonus' views as of any subsequent date. While Sonus may elect to update forward-looking statements at some point, Sonus specifically disclaims any obligation to do so.
Sonus is a registered trademark of Sonus Networks, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.
Investor Relations: Media Relations:
Jocelyn Philbrook Sarah McAuley
978-614-8672 978-614-8745
jphilbrook@sonusnet.com smcauley@sonusnet.com
SOURCE Sonus Networks, Inc.
----------------------------------------------
investors
Jocelyn Philbrook
+1-978-614-8672
jphilbrook@sonusnet.com
media
Sarah McAuley
+1-978-614-8745
smcauley@sonusnet.com
SCLD 1.15 SteelCloud Joins BlackBerry Alliance Program and Launches Product Offering to Support BlackBerry Enterprise Server in the Small and Medium Business Market
Jun 19, 2007 8:30:00 AM
HERNDON, Va., June 19 /PRNewswire-FirstCall/ -- SteelCloud, Inc. (Nasdaq: SCLD), a leading engineering and manufacturing integrator of network centric and embedded computing solutions, today announced it has joined the BlackBerry(R) Solution Provider Alliance Program. In conjunction with joining the program, SteelCloud also announced that it has designed and produced a unique product line -- the SteelCloud SteelWorks(TM) Mobile Server for BlackBerry(R) Enterprise Server from Research In Motion (RIM) (Nasdaq: RIMM; TSX RIMM). The product combines SteelCloud's specially-designed hardware and software with the BlackBerry(R) Enterprise Server software in a unique package designed for small-to-medium businesses (SMB).
SteelCloud's solution gives users the ability to purchase, or lease for a very low monthly fee, a complete hardware and software solution that incorporates the BlackBerry Enterprise Server software with SteelCloud's SteelWorks(TM) software and works with the common e-mail server software used by most organizations. SteelCloud's SteelWorks(TM) software includes a unique Installation Wizard that easily walks non-technical users through the installation process in approximately 30 minutes. Other SteelWorks(TM) features include:
-- MailChoice(TM) allowing the user to select Microsoft(R) Exchange,
IBM(R) Lotus(R) Domino(R) or Novell(R) GroupWise(R) e-mail servers
-- SteelRestore(TM), which performs backup, restore and rollback in case
of failure
-- SureAudit(TM), which guarantees the number of purchased licenses are
not exceeded
"The SMB market is looking for a low-cost mobile wireless email solution that is easy to use and that does not require highly-technical personnel for operation and maintenance," said Clifton W. Sink, SteelCloud CEO and President. "We have made a significant investment to bring this product to fruition. We believe that this offering will add yet another dimension to the value we contribute to this exciting market."
In the beta phase of a pilot program, over 100 units of the SteelCloud SteelWorks(TM) Mobile Server for BlackBerry Enterprise Server have been sold. This robust pilot program allowed SteelCloud to further refine the product prior to today's general release.
About SteelCloud
SteelCloud is an engineering and manufacturing integrator specializing in network centric and embedded computing solutions for the federal government and independent software vendors. The Company designs and manufactures specialized servers and appliances for federal integrators, software vendors and volume users. For both the government and commercial markets the Company delivers integration services and software focused on service desk, risk management and network management solutions. The Company's ISO 9001:2000 certified Quality Management System provides procedures for continuous quality improvement in all aspects of its business. Over its nearly 20-year history, SteelCloud has won numerous awards for technical excellence and customer satisfaction. SteelCloud can be reached at 703-674-5500. Additional information is available at http://www.steelcloud.com. E-mail: info@steelcloud.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward looking statements that involve a number of risks and uncertainties. It is possible that the assumptions made by management are not necessarily the most likely and may not materialize. In addition, other important factors that could cause actual results to differ materially include the following: business conditions and the amount of growth in the computer industry and general economy; competitive factors; ability to attract and retain personnel, including key sales and management personnel; the price of the Company's stock; and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-K and its quarterly reports on Forms 10-Q; and any reports on Form 8K. SteelCloud takes no obligation to update or correct forward-looking statements.
The BlackBerry and RIM families of related marks, images and symbols are the exclusive properties and trademarks of Research In Motion Limited.
SOURCE SteelCloud, Inc.
----------------------------------------------
William D. Hughes of SteelCloud
Inc.
+1-703-674-5560
whughes@steelcloud.com
UQM 3.96 UQM Technologies Introduces 150kW Propulsion System
Jun 19, 2007 8:30:00 AM
FREDERICK, Colo., June 19 /PRNewswire-FirstCall/ -- UQM Technologies, Inc. (Amex: UQM) announced today that it has developed and is taking orders for a new 150 kW (200 horsepower) peak power UQM(R) proprietary permanent magnet propulsion system. The new propulsion system is suitable for high performance automotive applications and heavy-duty commercial and military vehicles.
The propulsion system has a continuous power rating of 100kW (143 horsepower), delivers peak torque of 650 N-m (480 ft-lbs) and continuous torque of 400 N-m (295 ft-lbs) and has the highest power density of any of our propulsion systems. The system also features optimized four-quadrant performance, on-the-fly torque, speed and voltage control and system energy efficiency of over 90 percent over substantially all of its performance regime.
"This system will allow us to pursue additional market opportunities for those vehicle platforms with higher power requirements that we were previously unable to service," said Jon Lutz, Director of Engineering for UQM Technologies, Inc. "We are confident that this system will be well received by a wide range of potential customers who have not yet had the opportunity to experience the exceptional torque delivery, performance and efficiency of a UQM(R) propulsion system in their vehicle development programs."
UQM Technologies, Inc. is a developer and manufacturer of power dense, high efficiency electric motors, generators and power electronic controllers for the automotive, aerospace, medical, military and industrial markets. A major emphasis of the Company is developing products for the alternative energy technologies sector including propulsion systems for electric, hybrid electric, plug-in hybrid electric and fuel cell electric vehicles, under-the-hood power accessories and other vehicle auxiliaries and distributed power generation applications. The Company's headquarters, engineering and product development center, and motor manufacturing operation are located in Frederick, Colorado. For more information on the Company, please visit its worldwide website at http://www.uqm.com.
This Release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These statements appear in a number of places in this Release and include statements regarding our plans, beliefs or current expectations, including those plans, beliefs and expectations of our officers and directors with respect to, among other things the development of markets for our products and the adequacy of our cash balances and liquidity to meet future operating needs. Important Risk Factors that could cause actual results to differ from those contained in the forward-looking statements are contained in our Form 10-K filed May 17, 2007, which is available through our website at http://www.uqm.com or at http;//www.sec.gov.
SOURCE UQM Technologies, Inc.
----------------------------------------------
John Baldiserra of BPC Financial Marketing
1-800-368-1217
for UQM Technologies
Inc.; or Donald A. French of UQM Technologies
Inc.
+1-303-278-2002
GENR 2.80 Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
Jun 19, 2007 8:30:00 AM
PLYMOUTH MEETING, Pa., June 19 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that it will present a poster on trodusquemine (MSI-1436), its novel anti-obesity compound, during the American Diabetes Association (ADA) 67th Scientific Sessions, June 22 to 25 in Chicago.
The abstract, # 1801-P, is titled, "Trodusquemine is a Multiple Pathway Inhibitor that Causes Differential Weight Loss, Reduces Adiposity, and Improves Plasma Insulin and Leptin Levels."
The poster will be available from Saturday, June 23 through Monday, June 25 during the times the General Poster Session is open to conference attendees. Representatives from Genaera will be available to discuss the poster on Sunday, June 24 from 6:15 p.m. to 7:30 p.m. (CT) and on Monday, June 25 from 12:00 p.m. to 2:00 p.m. (CT).
For more information online, please visit: http://scientificsessions.diabetes.org/index.cfm?fuseaction=Custom.Content&Men uID=1000
About Trodusquemine (MSI-1436)
Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.
About Genaera
Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (or MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune for a second core program that is presently undergoing Phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. http://www.genaera.com.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
SOURCE Genaera Corporation
----------------------------------------------
investor relations
Genaera Corporation
+1-610-941-5675; or media
Susan Neath of Porter Novelli Life Sciences
+1-619-849-6007
sneath@pnlifesciences.com
PRZ .37 IPS Appoints John J. Karazim, II, M.D. as Chief Medical Officer
Jun 19, 2007 8:30:00 AM
ORLANDO, Fla., June 19 /PRNewswire-FirstCall/ -- Integrated Pain Solutions, LLC (IPS), a wholly owned subsidiary of PainCare Holdings, Inc. (Amex: PRZ), today announced the appointment of John J. Karazim, II, M.D. as IPS' Chief Medical Officer.
Reporting directly to IPS President, Maria R. McAfee, Dr. Karazim is charged with providing strategic clinical direction and managerial oversight of the Company's pain-focused managed services, medical policies and programs to include ensuring the highest quality continuum of care and services for patients through daily utilization and case management file reviews; participating in review processes of IPS' national privileged provider network; developing and/or refining, as necessary, IPS' prescribed clinical pathways; assessing clinical outcomes and collective statistical data to determine new or revised clinical protocols and guidelines; and providing thorough leadership and support to IPS customers, providers, clinical advisors and senior executives.
"Aside from his impeccable credentials and wealth of medical practice experience, Dr. Karazim brings IPS deep industry knowledge and an innate appreciation for the business of medicine and the need for effective integration of healthcare management -- making him an ideal choice to lead IPS as its new Chief Medical Officer," stated McAfee. "We are very pleased and proud to welcome him to IPS and trust that he will prove to be a vital member of our team as we continue to make positive changes in how chronic and severe pain is understood, addressed and efficiently treated."
A Diplomate of the National Board of Medical Examiners, American Board of Internal Medicine and the American Board of Emergency Medicine, Dr. Karazim also holds distinction as a Member of the American College of Physicians, Fellow of the American College of Emergency Physicians, Member of the American College of Sports Medicine, Member of the American Hospital Association, Member of the Michigan State Medical Society, Member of the Oakland County Medical Society, Fellow of the Back Pain Society and Member of the National Institute for Spinal Rehabilitation.
In addition to his new post at IPS, Dr. Karazim also serves as Medical Director of Dynamic Rehabilitation Centers, Inc. (DRC), an affiliate of PainCare Holdings. DRC is Michigan's most comprehensive spinal rehabilitation practice specializing solely in the treatment of sub-acute and chronic back and neck pain, and one of the largest, physician-based, MedX rehabilitation facilities in the world. In addition, Dr. Karazim also serves as a staff physician, Department of Internal Medicine, at Crittenden Hospital in Michigan, as well as Medical Director of Evergreen Home Health Care. He is a frequent guest lecturer at hospitals and medical learning institutions around the country and has served as a Clinical Assistant Professor at Oakland University, School of Health Sciences. He was also the Medical Director of the Meadowbrook Health Enhancement Institute of Oakland University focusing on chronic disease management through risk factor modification, rehabilitation and exercise. Dr. Karazim earned a Bachelor of Arts degree from Albion College and a Medical Degree from Wayne State University, School of Medicine.
About Integrated Pain Solutions (IPS)
Integrated Pain Solutions (IPS), a wholly-owned subsidiary of PainCare Holdings, Inc., is the first and only managed services organization offering a multidisciplinary healthcare network focused on pain management to payor organizations, such as insurance and workers' compensation carriers and unions. IPS reduces costs and increases quality of life by providing highly credentialed physicians and centers of excellence on pay-for-performance incentives, a continuum of care that begins with care coaching, a shared financial and clinical data warehouse, and evidence-based clinical outcome measurements to determine the most effective pain-management plan. For more information, please visit www.integratedpainsolutions.net.
About PainCare Holdings, Inc.
Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices and ambulatory surgery centers, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.
Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. Through Integrated Pain Solutions, the Company is engaged in pioneering the nation's first Managed Services Organization that offers a multi-disciplinary healthcare network focused on the treatment of pain. For more information on PainCare Holdings, please visit www.paincareholdings.com.
Safe Harbor Statement
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management. These forward-looking statements, which may include statements regarding our future financial performance or results of operations, including expected revenue growth, cash flow growth, future expenses, future operating margins and other future or expected performance, are subject to the following risks: the acquisition of businesses or the launch of new lines of business, which could increase operating expenses and dilute operating margins; the inability to attract new patients by our owned practices, the managed practices and the limited management practice; increased competition, which could lead to negative pressure on our pricing and the need for increased marketing; the inability to maintain, establish or renew relationships with physician practices, whether due to competition or other factors; the inability to comply with regulatory requirements governing our owned practices, the managed practices and the limited management practices; that projected operating efficiencies will not be achieved due to implementation difficulties or contractual spending commitments that cannot be reduced; and to the general risks associated with our businesses.
In addition to the risks and uncertainties discussed above you can find additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements in the reports that we have filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release represent our judgment as of the date of this release and you should not unduly rely on such statements. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in the filing may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
FOR MORE INFORMATION, PLEASE CONTACT:
Media Relations
Suzanne Beranek, APR, Beranek Communications, LLC
407-475-0763 or via email at suzanne@beranekcommunications.com
FOR MORE INFORMATION, PLEASE CONTACT:
Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist
Elite Financial Communications Group
407-585-1080 or via email at prz@efcg.net
SOURCE Integrated Pain Solutions, LLC
----------------------------------------------
Suzanne Beranek
APR of Beranek Communications
LLC
+1-407-475-0763
suzanne@beranekcommunications.com; or Dodi Handy
President and CEO; or Daniel Conway
Chief Strategist
+1-407-585-1080
prz@efcg.net
both of Elite Financial Communications Group
all for Integrated Pain Solutions
LLC
SANM 3.47 Sanmina-SCI Selects Chennai For Expansion In India
One of the World's Largest Electronics Manufacturers Unveils Plans to Build State-of-the-Art Manufacturing Technology Campus In Oragadam Near Chennai
Jun 19, 2007 8:30:00 AM
SAN JOSE, Calif., June 19 /PRNewswire-FirstCall/ -- Sanmina-SCI Corporation (Nasdaq: SANM), a leading global electronics manufacturing services (EMS) company, today announced that it has signed a Memorandum of Understanding (MoU) with the Government of Tamil Nadu, India, selecting Oragadam near Chennai, as the location for Sanmina-SCI's first state-of-the-art manufacturing technology campus in India. The campus, when completed, will provide leading Original Equipment Manufacturers (OEMs) in the medical, defense and aerospace, communications, automotive, and multimedia and consumer markets with cutting-edge manufacturing services that are especially tailored to the exacting technical and quality requirements of these market segments. At a press conference held in the city, the company formally launched its operations in India in the presence of Mr. Shaktikanta Das, Industries Secretary, Government of Tamil Nadu.
Located in Oragadam near Chennai, Sanmina-SCI's campus will cover approximately 100 acres and will be a designated Special Economic Zone (SEZ) as defined by Government of India regulations. The new campus will strengthen Sanmina-SCI's global manufacturing strategy enabling the company to better serve the growing Indian market as well as provide another source of cost- competitive technology products to Sanmina-SCI's customers around the world. In a phased manner, Sanmina-SCI's existing activities in Chennai, such as engineering, supply chain management and IT services, will relocate to the campus, enabling the company to offer its customers a comprehensive range of services from an integrated campus.
"Today's announcement reiterates Sanmina-SCI's long-term commitment to the Indian marketplace and our commitment to support our customers with innovative technology and advanced manufacturing solutions in key locations around the world," said Hari Pillai, President of Global EMS Operations, Sanmina-SCI. "The long-term opportunities in the fast growing Indian market are very attractive. We look forward to joining with the people and Government of Tamil Nadu as we embark on this new phase of our presence in India. We are very pleased to make this announcement and today celebrate this important milestone with our employees and customers."
"As one of the largest and fastest growing economies in the world, India is emerging as an economic powerhouse that is expected to continue to grow rapidly in the next few years," said Kumaran Subramaniam, Managing Director of Sanmina-SCI India. "India is both a source of skilled, technical talent and an attractive market that is expected to become one of the major global players of the 21st century. Sanmina-SCI's decision to establish a strong presence in India reaffirms the long-term significance of this important market."
Sanmina-SCI is one of the world's largest and most diverse EMS providers, offering end-to-end manufacturing solutions to branded technology companies. The company's expansion into India extends many years of manufacturing and engineering excellence that is proven to help customers reduce market risks and decrease time-to-market.
About Sanmina-SCI
Sanmina-SCI Corporation is a leading electronics contract manufacturer serving the fastest-growing segments of the global Electronics Manufacturing Services (EMS) market. Recognized as a technology leader, Sanmina-SCI provides end-to-end manufacturing solutions, delivering unsurpassed quality and support to OEMs primarily in the communications, defense and aerospace, industrial and medical instrumentation, multimedia and consumer, computing and storage, and automotive technology sectors. Sanmina-SCI has facilities strategically located in key regions throughout the world. More information regarding the Company is available at http://www.sanmina-sci.com.
Sanmina-SCI Safe Harbor Statement
The foregoing, including the discussion regarding the Company's future prospects, contains certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with economic conditions in the electronics industry, particularly in the principal industry sectors served by the Company, changes in customer requirements and in the volume of sales to principal customers, the ability of Sanmina-SCI to effectively assimilate acquired businesses and achieve the anticipated benefits of its acquisitions, and competition and technological change. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors, including factors set forth in the Company's fiscal year 2006 Annual Report on Form 10-K filed on January 3, 2007 and the other reports, including quarterly reports on Form 10-Q and current reports on Form 8-K, that the Company files with the Securities Exchange Commission.
SOURCE Sanmina-SCI Corporation
----------------------------------------------
Michael Kovacs
Director
Corporate Marketing
+1-408-964-3142
michael.kovacs@sanmina-sci.com
or Paige Bombino
Investor Relations
+1-408-964-3610
both of Sanmina-SCI Corporation
TIBX 8.93 TIBCO Transforms Order Management Platform for Swisscom Mobile
Extension of CRM and BSS Integration Built on TIBCO Platform Delivers Further Cost Savings
Jun 19, 2007 8:30:00 AM
LONDON, June 19 /PRNewswire-FirstCall/ -- TIBCO Software Inc. (Nasdaq: TIBX) announced today that Swisscom Mobile, Switzerland's largest operator of mobile phones, has completed the extension of its order management platform, further enhancing its business support systems (BSS) integration and supporting the extended capabilities offered in its customer relationship management (CRM) system, a core BSS component.
The completion of the project, which centres on TIBCO BusinessWorks(TM), TIBCO BusinessWorks(TM) Collaborator and TIBCO Enterprise Message Service(TM) will shorten time-to-market of consumer products and services; increase sales from additional consumer offerings; improve and simplify customer account management and enhance customer data quality on which future offerings can be built.
Chris Manton, Head of Enterprise Application Integration, Swisscom Mobile, said: "The new automated order management platform from TIBCO will allow us to provide greater flexibility and service choices to existing and prospective customers, while remaining competitive and reducing customer churn."
The latest phase of the project migrates Swisscom Mobile's CRM and current EAI platform to a fully automated Order Management system for increased performance and flexibility and more scalable error handling. It standardises the structure of horizontal business services for use during various processes. In previous phases, TIBCO focused on a point-to-point solution via EAI, involving connectivity, messaging, monitoring and the structure of basic services. This was followed by an initial order management project, which has now been extended.
Murat Sonmez, executive vice president, Global Field Operations, TIBCO, said: "Transforming Swisscom Mobile's work on its order management platform will help it quickly and proactively respond to constantly changing consumer demands in its marketplace. Through TIBCO's work on its platform, Swisscom Mobile is able to create a more efficient and cost effective way of doing business."
About TIBCO
TIBCO Software Inc. (Nasdaq: TIBX) provides enterprise software that helps companies achieve service-oriented architecture (SOA) and business process management (BPM) success. With over 3,000 customers, TIBCO has given leading organisations around the world better awareness and agility -- what TIBCO calls The Power of Now(R). To learn more, contact TIBCO at +1 650-846-1000 or on the Web at http://www.tibco.com.
TIBCO, TIBCO BusinessWorks, TIBCO BusinessWorks Collaborator, TIBCO Enterprise Message Service, The Power of Now, and TIBCO Software are trademarks or registered trademarks of TIBCO Software Inc. in the United States and/or other countries. All other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.
SOURCE TIBCO Software Inc.
----------------------------------------------
Declan Waters of TIBCO Software
01628-786-844
dwaters@tibco.com; or Nick Spencer of NSPR
01628-502-606
nick@nspr.co.uk
for TIBCO Software Inc.
TIVO 5.96 TiVo Sells Another Stop||Watch(TM) Ratings Service Subscription
Media Performance Monitor America to use Subscription to Maximize Client's ROI
Jun 19, 2007 8:30:00 AM
ALVISO, Calif. and NEW YORK, June 19 /PRNewswire-FirstCall/ -- TiVo Inc. (Nasdaq: TIVO), the creator and a leader in advertising solutions and television services for digital video recorders (DVRs), today announced that it has sold another subscription to its Stop||Watch(TM) ratings service. Media Performance Monitor America (MPMA), a leading media performance monitoring firm, will use the Stop||Watch ratings service to further enhance its monitoring capacities with the aim of maximizing advertising investment returns for its clients.
The Stop||Watch ratings service, a comprehensive second-by-second program and commercial ratings research product, will serve MPMA by providing the company with a comprehensive collection of TV audience data, granting MPMA greater insight into the viewing behavior of today's TV audiences. Through detailed analysis of viewers' commercial-watching patterns, MPMA, as a firm working exclusively with advertisers, will have a unique perspective into delivering ideal return-on-investment (ROI) solutions to clients.
"By purchasing a subscription to the Stop||Watch ratings service, we are committing even further to the success of our advertising clients by augmenting our media performance management analytics with TiVo's respected research," said P. J. Leary, CEO, MPMA. "With the Stop||Watch ratings service, we will have a wealth of invaluable audience data at our disposal for more detailed parsing of advertising effectiveness."
"MPMA's subscription to the Stop||Watch ratings service is yet another example of TiVo's dedication to the advancement and evolution of the advertising industry," said Todd Juenger, Vice President & General Manager, TiVo Audience Research & Measurement. "We are thrilled that MPMA has chosen to leverage the Stop||Watch ratings service in their consultative service providing even deeper insights into the media value delivered to their clients. It is telling that leading firms such as MPMA, who make their living helping clients improve media ROI, are incorporating Stop||Watch into their analysis."
TiVo Audience Research & Measurement data is derived from a daily, aggregate, anonymous, stratified random sample of 20,000 TiVo units -- from which the second-by-second "clickstream" of behavior and viewership is collected and assessed. The Stop||Watch ratings service is offered via an easily sortable database of ratings for nationally run programs and advertisements in primetime and daytime, dating back to September 2006. The Stop||Watch ratings service was introduced in February 2007. Stop||Watch includes data for: Total Viewing, Live Viewing, Timeshifted Viewing (less than 1 hour, 1-6 hours, 6-24 hours, 24-48 hours, 2-7 day, and 7-14 day delay), Program Ratings, Commercial Ratings and a Commercial Viewership Index.
About TiVo Inc.
Founded in 1997, TiVo (NASDAQ: TIVO) pioneered a brand new category of products with the development of the first commercially available digital video recorder (DVR). Sold through leading consumer electronic retailers, TiVo has developed a brand which resonates boldly with consumers as providing a superior television experience. Through agreements with leading satellite and cable providers, TiVo also integrates its DVR service features into the set- top boxes of mass distributors. TiVo's DVR functionality and ease of use, with such features as Season Pass(TM) recordings, WishList(R) searches, and TiVo(R) KidZone, have elevated its popularity among consumers and have created a whole new way for viewers to watch television. With a continued investment in its patented technologies, TiVo is revolutionizing the way consumers watch and access home entertainment. Rapidly becoming the focal point of the digital living room, TiVo's DVR is at the center of experiencing new forms of content on the TV, such as broadband delivered video, music and photos. With innovative features, such as TiVoToGo(TM) transfers and online scheduling, TiVo is expanding the notion of consumers experiencing "TiVo, TV your way.(R)" The TiVo(R) service is also at the forefront of providing innovative marketing solutions for the television industry, including a unique platform for advertisers and audience measurement research. The company is based in Alviso, Calif.
TiVo, Season Pass, WishList, Series2, Series3, TiVoToGo, Stop||Watch, 'TiVo, TV your way' and the TiVo logo are trademarks or registered trademarks of TiVo Inc. or its subsidiaries worldwide. (C) 2007 TiVo Inc. All rights reserved.
About MPMA
Started in 2003, Media Performance Monitor America (MPMA) is a leading media performance auditor. MPMA works for advertisers and delivers a higher return for their clients' media investment. Currently auditing National TV, Spot TV, Spot Radio, National Print and Internet advertising, MPMA has 26 clients and is based in New York City. MPMA is owned by Thomson-Intermedia PLC, a publicly traded company on the London Stock Exchange (Ticker Symbol: THN).
SOURCE TiVo Inc.
----------------------------------------------
Whit Clay for TiVo Inc.
+1-212-446-1864
wclay@sloanepr.com
RMTR 3.32 Ramtron Expands FRAM-Enhanced(TM) MCU Family With Industry Standard, 8051-Based Drop-In
Unique Nonvolatile Data Storage/Processing System Enables Easy Device Migration
Jun 19, 2007 8:30:00 AM
COLORADO SPRINGS, CO -- (MARKETWIRE) -- 06/19/07 -- Ramtron International Corporation (NASDAQ: RMTR), a leading developer and supplier of nonvolatile ferroelectric random access memory (FRAM) and integrated semiconductor products, today launched the VRS51L3174, an 8051-based microcontroller with 8 kilobytes (KB) of nonvolatile FRAM memory that drops into industry standard 44-pin QFP sockets for easy device migration. Ramtron has added FRAM to its fast and flexible Versa 8051s for a quick and reliable nonvolatile data storage and processing system that only a FRAM-Enhanced(TM) MCU can provide.
The VRS51L3174 combines 8KB of FRAM memory with a fully-integrated, high-performance system-on-chip. Features include an advanced 40-MIPS, single-cycle 8051-core, 64KB Flash with in-system/in-application programming, 4KB SRAM, digital signal processing (DSP) extensions and a robust digital peripheral set. Operating at 3.3 volts over the entire industrial temperature range, the VRS51L3174 is the ideal embedded data acquisition solution, targeting a wide array of advanced applications from sensors and metering to industrial control, instrumentation and medical devices.
VRS51L3174 Features
8K x 8 FRAM: 8KB of true nonvolatile RAM (no battery/super cap required to maintain data) mapped into the VRS51L3174's XRAM memory for easy access, fast writes and essentially unlimited endurance.
40MHz, Single-Cycle 8051 Processor: This is one of the fastest 8-bit processors on the market. Its advanced core can deliver up to 40 MIPS throughput and is instruction-compatible with standard 8051s, for smooth device migration.
MULT/ACCU/DIV Unit with 32-bit Barrel Shifter: This hardware calculation engine significantly outperforms 8-bit processors when executing DSP operations (FIR filtering, sensor output linearization, multiple-byte arithmetic operations, etc). It performs 16-bit signed multiplication and 32-bit addition in one cycle and 16-bit signed division in 5 cycles. The barrel shifter enables logic/arithmetic shift operations.
40MHz Internal Oscillator: The internal oscillator cuts system costs by eliminating the need for an external crystal oscillator.
USB-JTAG Interface: For user-friendly and quick device programming and real-time, in-circuit debugging/emulation of the user application without the need for a costly emulator.
Dual UARTs with Baud Rate Generator: The universal asynchronous receiver/transmitters operate at up to 1.25 Mbps. Each UART incorporates a dedicated baud rate generator with 20-bit equivalent resolution.
Enhanced SPI: The communication speed on the serial peripheral interface can be configured up to 20 Mbps and transactions are adjustable from 1 to 32 bits.
PWCs: Two pulse width counter modules provide advanced timer control, simplifying event duration measurement.
PWMs: Eight pulse width modulators with up to 16-bit adjustable resolution. Each PWM includes its own timer, which can also be used as general purpose timers.
Other support peripherals include an I�C interface, three 16-bit general purpose timers/counters with three timer capture inputs, a watchdog timer, and 49 interrupts that share 16 interrupt vectors. The VRS51L3174 is available in a QFP-44 package that is pin-compatible with standard 8051 MCUs.
FRAM instead of Flash/EEPROM for nonvolatile data storage
FRAM simplifies the design cycle by eliminating the code overhead accompanying Flash data storage, and the limited endurance and drawn out write cycles of Flash/EEPROM. Unlike Flash, FRAM bytes can be modified without first erasing an entire sector, rendering it easier to use. And unlike Flash/EEPROM, FRAM provides virtually unlimited read/write cycles and fast data writes.
Pricing and Availability
The VRS51L3174 is currently sampling and costs under $5 for quantities of 10,000. For more information about Ramtron's FRAM-Enhanced(TM) MCUs, visit www.ramtron.com/vrs3xxx/.
About Ramtron
Ramtron International Corporation, headquartered in Colorado Springs, Colorado, is a fabless semiconductor company that designs, develops and markets specialized semiconductor memory and integrated semiconductor solutions used in a wide range of product applications and markets worldwide. For more information, visit www.ramtron.com.
For a 300-dpi product photo, visit www.ramtron.com/doc/Press/Images.asp.
Add to Digg Bookmark with del.icio.us Add to Newsvine
CONTACT:
Catherine Cohen
(514) 871-2447 x 112
Email Contact
DANKY 1.07 Danka Announces Refinancing Agreement Totaling $145 million with GE Corporate Lending
Jun 19, 2007 8:30:00 AM
Copyright Business Wire 2007
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--
Danka Business Systems PLC (NASDAQ:DANKY) today announced that it has entered into an agreement with GE Corporate Lending for a new senior secured credit facility totaling $145 million that would be used, together with the proceeds of the Company's previously completed sale of its European operations, to significantly reduce and refinance the Company's existing indebtedness.
Upon completion of this financing, the Company expects to reduce its overall indebtedness to approximately $120 million, down from $254 million. It will also reduce annual interest expense to approximately $13 million from the current $29 million.
"Today's agreement with GE Corporate Lending represents another significant milestone in the reshaping of Danka," said A.D. Frazier, Chairman and Chief Executive Officer. "This credit facility, along with the other important financial and operational steps we have taken in the past year, will provide Danka with the appropriate long-term flexibility from which to grow our business. It also reaffirms the Company's commitments to our valued vendors and existing customers, and significantly enhances the ability of our talented team of employees to compete for and win new customers, as well as deliver even greater value."
The new credit facility includes a $40 million Senior Secured Revolving Credit Facility, a $60 million Senior Secured Term Loan and a $45 million Second Lien Loan.
Completion of the financing is subject to a number of customary closing conditions. The Company expects the transaction to close by June 22, 2007. Representing Danka in the transaction was the investment banking firm Houlihan Lokey and the law firm Skadden, Arps, Slate, Meagher & Flom.
About Danka
Danka delivers value to clients by using its expert technical and professional services to implement effective document information solutions. As one of the leading independent providers of enterprise imaging systems and services, the company enables choice, convenience, and continuity. Danka's vision is to empower customers to benefit fully from the convergence of image and document technologies in a connected environment. This approach will strengthen the company's client relationships and expand its strategic value. For more information, visit Danka's web site at www.danka.com.
About GE Corporate Lending
With $14 billion in assets, GE Commercial Finance Corporate Lending is one of North America's largest providers of asset-based, cash flow, structured finance and other capital solutions for mid-size and large companies. From over 30 offices throughout the U.S. and Canada, Corporate Lending specializes in serving the unique needs of borrowers seeking $20 million to $2 billion and more for working capital, growth, acquisitions, project finance and turnarounds. Visit www.gelending.com/clnews for more information.
Certain statements contained in this press release, including statements related to Danka's future business and financial performance, are forward-looking. Such statements reflect the current views of Danka with respect to future events and are subject to certain risks, uncertainties and assumptions that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward looking statements, which reflect management's analysis only as of the date they are made.
Danka is a registered trademark and Danka @ the Desktop is a trademark of Danka Business Systems PLC. All other trademarks are the property of their respective owners.
Source: Danka Business Systems PLC
----------------------------------------------
Danka
St. Petersburg
Cheley Howes
727-622-2760
or
Danka
London
Louis Kritzinger
44-207-605-0150
or
The Dilenschneider Group
Robert E. Swadosh
212-922-0900
AMCC 2.70 AMCC and Fulcrum Microsystems Demonstrate Industry's Highest Density Evaluation Platform for 10 Gigabit Ethernet SFP+ at NXTcomm
Companies Combine Space-Saving SFP+ Connectivity With Low-Latency Ethernet Switching in New Joint Reference Design Visit AMCC at NXTcomm -- Booth # 7536 at McCormick Place in Chicago
Jun 19, 2007 8:00:00 AM
Copyright Business Wire 2007
CHICAGO--(BUSINESS WIRE)--
Applied Micro Circuits Corporation (NASDAQ:AMCC), a global leader in embedded Power Architecture(TM) processing, optical transport and storage solutions, and Fulcrum Microsystems today announced a new jointly designed SFP+ 10 Gigabit Ethernet (GbE) switch reference design code named "Lassen" at NXTcomm, a leading telecommunications technology trade show taking place this week in Chicago.
The joint reference platform combines AMCC's QT2035S SFP+ physical (PHY) layer IC and its Power Architecture-based 440EPx CPU with Fulcrum's FocalPoint(R) FM2224 10 GbE switch chip and ControlPoint(TM) software suite. The reference design is the first to marry the space-saving SFP+ module form-factor, which is up to 30% smaller than competing form factors, with a high-performance, low latency switch.
The single plane, joint reference design is a 24-port, pizza-box style switch with 24 SFP+ ports. The AMCC QT2035S PHY enables all reaches of 10 GbE in an SFP+ form factor including SR, LR, LRM and ER. In addition, 10 GbE over twin-axial copper cable is also supported. New levels of integration include the Fulcrum(TM) software stack being ported to AMCC's PowerPC 440EPx CPU. The 440EPx embedded processor features speeds up to 667 MHz with on-chip security and is ideal for high-speed networking applications. The Fulcrum switch chip ensures wire-rate switching performance with the industry's lowest latency of 200 ns. The combination provides the highest density and highest performance 10 GbE switching solution available on the market today.
"As 10 Gigabit Ethernet moves deeper into MAN and WAN environments, companies such as Google, AOL and Yahoo, who run massive data centers, are seeking compact, high density switches that provide the highest levels of access performance as the network convergence trend continues to accelerate," said Mitch Kahn, Vice President of Marketing, Transport Products, AMCC. "This joint reference design with its lower cost, lower power consumption and smaller footprint can provide a complete processing and switching solution for our customers."
"With SFP+ gaining momentum as the new MSA standard for next-generation 10 Gigabit Ethernet, 'Lassen' is a feature-complete reference design that includes both our FM2224 10-Gigabit Ethernet switch chip and our ControlPoint software suite," said Mike Zeile, Vice President of Marketing for Fulcrum Microsystems. "Working with AMCC and Intel on 'Lassen' marks another important step in the development of an ecosystem in which 10 Gigabit Ethernet can become the standard for enterprise networks."
NXTcomm visitors to AMCC's booth # 7536 will be able to view a live demonstration of the "Lassen" SFP+ 24 point joint reference design. Schematics and layout files for the platform will be available in August.
About AMCC
AMCC is a global leader in network and embedded PowerPC(TM) processing, optical transport and storage solutions. Our products enable the development of converged IP-based networks offering high-speed secure data, high-definition video and high-quality voice for carrier, metropolitan, access and enterprise applications. AMCC provides networking equipment vendors with industry-leading communications processing, Ethernet, SONET and switch fabric solutions. AMCC is also the leading vendor of high-port count SATA RAID controllers enabling low-cost, high-performance, high-capacity storage. AMCC's corporate headquarters are located in Sunnyvale, California. Sales and engineering offices are located throughout the world. For further information regarding AMCC, please visit our web site at http://www.amcc.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as expects, anticipates, plans, believes, estimates, will or words of similar meaning. Such forward-looking statements, including statements relating to the products discussed in this press release, are subject to a number of risks and uncertainties, including the risk that the products may not be successfully or timely developed, completed or manufactured or achieve market acceptance, risks relating to general economic conditions, as well as the risks and uncertainties set forth in the Company's Annual Report on Form 10-K, and in the Company's other SEC filings. As a result of these risks and uncertainties, actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and AMCC does not assume any obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise.
AMCC is a registered trademark of APPLIED MICRO CIRCUITS CORPORATION. PowerPC is a trademark licensed by the IBM Corporation. Power Architecture is a trademark licensed by Power.org. All other names are for informational purposes and may be trademarks of their respective owners.
Source: Applied Micro Circuits Corporation
----------------------------------------------
Applied Micro Circuits Corporation
Austin
Rich Flair
512-372-1711
rflair@amcc.com
or
Media Relations:
The Bernard Group
Tom Price
512-327-2195 or (c) 512-415-7744
tprice@bernardgroup.com
OVRL 2.65 Overland Storage Announces Availability of LTO4 Tape Drive Technology
Jun 19, 2007 7:30:00 AM
SAN DIEGO, June 19 /PRNewswire-FirstCall/ -- Overland Storage, Inc. (Nasdaq: OVRL), a leading provider of tape- and disk-based backup and recovery solutions, has announced that its NEO Series and ARCvault families of tape automation will use HP fourth-generation linear open-tape drives, known as LTO4.
"HP was chosen as Overland's LTO4 tape drive supplier due to the relationship that exists between the two companies and HP's leadership in the LTO tape drive market," said Scott McClendon, interim president and CEO of Overland Storage.
Additionally, HP LTO4 tape drives, which offer device-level encryption, improved performance, and higher capacity than previous LTO generations, will be integrated into the HP StorageWorks MSL6000 tape libraries manufactured by Overland under an OEM contract.
"HP values its relationship with Overland both as a supplier for the HP StorageWorks MSL line and as a customer of our tape drives," said Bob Wilson, vice president, Nearline, StorageWorks Division, HP. "We look forward to supporting Overland in introducing LTO4 tape drive technology in their products."
"The combination of improvements in capacity and performance as well as support for data encryption makes LTO4 a compelling enhancement for customers looking for faster backup and/or improved data retention," said Peri Grover, director of product management at Overland Storage. "With LTO4, our NEO SERIES(R) and ARCvault(TM) solutions will scale from 9.6 terabytes to 1.6 petabytes and reach speeds of up to 20 terabytes per hour, satisfying the needs of customers of all sizes."
"The introduction of LTO4 represents another compelling event in the storage industry," added Grover. "The decision to add LTO4 support to the MSL6000 series from HP reflects the ongoing demand for the products and how well these libraries have held up over time."
Availability and Pricing
Overland's family of NEO tape libraries will begin shipping this month with a starting MSRP of $16,615. Availability of LTO4 configurations of the ARCvault tape libraries will follow within 30-45 days.
About Overland Storage
Now in its 26th year, Overland Storage is a market leader and innovative provider of simply protected storage solutions - smart data protection appliances and software modules designed to work together, affordably, to ensure that information is automatically safe, readily available and always there. Overland's award-winning data protection solutions include the ULTAMUSTM RAID SERIES of affordable, high-capacity storage; REO SERIES(R) of disk-based backup, recovery and VTL appliances; and the NEO SERIES(R) and ARCvault(TM) family of tape automation solutions. Overland sells its products through leading OEMs, commercial distributors, storage integrators and value- added resellers. For more information, visit Overland's web site at http://www.overlandstorage.com.
Except for the factual statements made herein, the information contained in this news release consists of forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism and satisfaction with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, identify forward- looking statements, but their absence does not mean that a statement is not forward looking. Such forward-looking statements are not guarantees of performance and the company's actual results could differ materially from those contained in such statements. Factors that could cause or contribute to such differences include possible delays in new product introductions and shipments by the company including the new ULTAMUS and ARCvault product lines; possible delays in enhancements and new offerings in the company's REO line; market acceptance of the company's other new product offerings; the performance of the company's newly restructured management team; the timing and market acceptance of new product introductions by competitors; unexpected inventory charges resulting from the termination of the relationship with the company's former outsourced manufacturing partner; inefficiencies and excessive manufacturing costs in the early stages of the return of production to the company's San Diego facility; worldwide information technology spending levels; unexpected shortages of critical components; rescheduling or cancellation of customer orders; loss of a major customer; the timing and amount of licensing royalties; general competition and price pressures in the marketplace; the company's ability to control costs and expenses; and general economic conditions. Reference is also made to other factors set forth in the company's filings with the Securities and Exchange Commission, including the "Risk Factors," "Management's Discussion and Analysis" and other sections of the company's Forms 10-K and 10-Q currently on file with the SEC. These forward-looking statements speak only as of the date of this release and the company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Overland, Overland Storage, REO Series, REO, NEO Series, NEO, ARCvault Series, ARCvault and ULTAMUS are trademarks of Overland Storage, Inc.
SOURCE Overland Storage, Inc.
----------------------------------------------
Sue Hetzel of HetzelMeade Communications
sue@hetzelmeade.com +1-760-434-9927
for Overland Storage
Inc.
EXTR 3.84 Extreme Networks Joins New Carrier Ethernet Ecosystem to Provide Service Provider Networks with Improved Economics, Scalability
Ecosystem provides partnering framework for Solution Providers to adopt Ethernet as preferred means of information transport in carrier networks
Jun 19, 2007 7:30:00 AM
SANTA CLARA, Calif., June 19 /PRNewswire-FirstCall/ -- Extreme Networks, Inc. (Nasdaq: EXTR) today announced that it has joined with the new Carrier Ethernet Ecosystem spearheaded by Nortel. The Ecosystem's goal is to focus on the interoperability necessary to help carriers to meet the explosion in demand on metro area networks from video, VoIP and other real-time communications. As part of this, the Ecosystem will focus on Provider Backbone Bridging Traffic Engineering (PBB-TE), which provides scalability and economic enhancements to Ethernet also known as Provider Backbone Transport.
"We are excited to be a part of the Carrier Ethernet Ecosystem and to work within this framework to accelerate the adoption of PBT-enabled carrier solutions," said Peter Lunk, director of service provider marketing for Extreme Networks(R). "The PBT interoperability demonstration between Extreme and Nortel scheduled at NXTcomm in Chicago this week is a great example of what we can get done by working together."
The Ecosystem will bring together industry hardware and software vendors as well as component and tool suppliers to participate in creating interoperable carrier Ethernet solutions. To learn more about it, please visit http://www.nortel.com/ecosystem
For more information on Extreme Networks carrier grade Ethernet solutions, visit: http://www.multidimensionalethernet.com.
Extreme Networks, Inc.
Extreme Networks designs, builds, and installs Ethernet infrastructure solutions that solve the toughest business communications challenges. Our commitment to open networking sets us apart from the alternatives by delivering meaningful insight and unprecedented control to applications and services. We believe openness is the best foundation for growth, freedom, flexibility, and choice. We focus on enterprises and service providers who demand high performance, converged networks that support voice, video and data, over a wired and wireless infrastructure.
SOURCE Extreme Networks, Inc.
----------------------------------------------
Greg Cross of Extreme Networks Public Relations
+1-408-579-3483
gcross@extremenetworks.com
GERN 7.70 Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
Company's Second Cell Type for Clinical Development - Cardiomyocytes for Treatment of Heart Failure - is Subject of Feature Presentation at ISSCR Annual Meeting Other Presentations Document Continued Progress in Geron's Development of Cellular Products for Spinal Cord Injury, Diabetes and Orthopedic Applications
Jun 19, 2007 7:30:00 AM
Copyright Business Wire 2007
MENLO PARK, Calif.--(BUSINESS WIRE)--
Geron Corporation (Nasdaq: GERN) today reported that research documenting the scalable production, survival following engraftment and positive impact on cardiac function in infarcted rats was presented today for GRNCM1, the company's human embryonic stem cell (hESC)-based therapeutic for heart failure, at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Cairns, Australia.
The presentation was one of seven involving Geron scientists and collaborators that documented the company's progress in developing multiple therapeutic products from its hESC platform. Other presentations focused on the gene expression and neurotrophic protein secretion patterns of hESC-derived oligodendroglial progenitor cells for acute spinal cord injury, the functional characterization of hESC-derived islets for diabetes, and hESC-derived chondrocytes for arthritis and other orthopedic applications.
"We have made significant progress in the development of hESC-based therapeutics," said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. "GRNCM1 will be the second product we intend to develop clinically. Large animal proof of concept studies are imminent. With our most advanced cell type, GRNOPC1 for acute spinal cord injury, we remain on track for the filing of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration later this year pending the outcome of our ongoing safety studies. Lastly, we recently published our scalable method to produce GRNIC1, hESC-derived islets for diabetes. We presented data at the ISSCR Annual Meeting on a procedure to enhance the insulin-secreting potency of the cells that are currently in animal studies in our collaborator's laboratories at the University of Alberta. Geron remains at the forefront of taking embryonic stem cell-derived products into clinical development."
Cardiomyocytes for the Treatment of Heart Failure
The results of work performed in collaboration with Drs. Charles Murry and Michael Laflamme at the University of Washington were presented by Dr. Joseph Gold, Geron's director of stem cell biology. The presentation described efficient differentiation of cardiomyocytes from hESCs and their effectiveness in preventing the onset of heart failure in rodent infarct models. In the differentiation procedure, cardiomyocytes were generated using non-conditioned, serum-free media and a directed differentiation protocol that produces cells with the phenotypic, electrophysiological and contractile properties of human immature cardiomyocytes. The new protocol produces cardiomyocytes with high efficiency, yielding 10-100 fold more cardiomyocytes per undifferentiated hESC than conventional "embryoid body-based" protocols. The differentiation protocol produced cardiomyocyte populations of up to 70% purity at scales sufficient to enable both preclinical and early clinical development. Moreover, the final cardiomyocyte product could be cryopreserved and thawed with high viability.
When transplanted together with survival enhancement factors directly into the myocardial infarct zone of rats, the GRNCM1 cells survived for at least four weeks and formed grafts expressing key markers of human cardiomyocytes, including Beta myosin heavy chain. Echocardiographic and magnetic resonance imaging analysis showed that the animals transplanted with GRNCM1 cells had improved (smaller) end-left ventricular systolic and diastolic diameters, increased fractional shortening, improved infarct wall thickening and increased ejection fraction compared to control animals injected with factors alone or controls injected with non-cardiac cells derived from hESCs. These data show that engrafted GRNCM1 cells significantly improved heart function after myocardial infarction.
"This is animal proof of concept for our second therapeutic cell type," said Jane S. Lebkowski, Ph.D., Geron's senior vice president of regenerative medicine. "The fact that functional cardiomyocytes can be generated at a large scale and successfully cryopreserved provides another validation of our product-based business model. The model is for Geron to provide cell-based therapies as off-the-shelf products for the treatment of chronic degenerative diseases."
Oligodendroglial Progenitors for the Treatment of Spinal Cord Injury
The properties and functions of GRNOPC1, Geron's lead hESC product for the treatment of spinal cord injury, were discussed in four presentations at the ISSCR Annual Meeting. GRNOPC1 is a hESC-derived cell population containing oligodendroglial progenitor cells. Oligodendroglial cells are responsible for myelinating, or insulating, neurons, a critical function allowing unimpeded nerve impulse conduction.
Dr. Hans Keirstead with the University of California, Irvine, presented data showing that demyelination is a common finding in animal models of spinal cord contusion injury, the most common type of spinal cord injury occurring in humans, and that progressive demyelination continues even months after injury. Dr. Keirstead further described the differentiation of GRNOPC1 from hESCs and demonstrated that upon transplantation into rats with acute spinal cord injuries, GRNOPC1 stimulated extensive remyelination of neurons, improved neuronal survival and increased neurite outgrowth in damaged areas of the cord. This resulted in improved hind-limb locomotor activity.
Geron scientists presented additional studies showing that the production process for GRNOPC1 recapitulated the stages of oligodendroglial progenitor growth during human spinal cord development. By monitoring expression of specific genes during the production of GRNOPC1, researchers were able to document the emergence and specific identity of spinal cord oligodendroglial progenitors. Moreover, studies showed that GRNOPC1 secretes specific neurotrophic factors, including midkine, hepatocyte growth factor, activin A, transforming growth factor Beta and brain-derived neurotrophic factor. These factors induce growth of neurons and are likely to contribute to the therapeutic effects of GRNOPC1 after transplantation in the injured spinal cord.
"These studies document some of the multiple mechanisms by which GRNOPC1 may potentiate spinal cord repair," said R. Scott Thies, Ph.D., Geron's director of cell technologies. "Furthermore the results provide specific markers to monitor and control the quality of the production of GRNOPC1, a critical element in the development of therapeutic cell products."
Islet Cells for the Treatment of Diabetes
In another presentation, Geron scientists described procedures to produce islet-like clusters from hESCs, a potential treatment for diabetes. In the work recently published online in Stem Cells Express and in an upcoming issue of Stem Cells, Geron scientists described a multistage protocol to differentiate hESCs into key cell types of the pancreas, including ductal, exocrine and endocrine cells. The endocrine cells appeared as bud-like clusters resembling the islets of Langerhans and included the major islet cell types that produce the hormones insulin, glucagon and somatostatin. Upon exposure to increased concentrations of glucose, the islet-like clusters secreted insulin. When transplanted into diabetic mice, the hESC-derived pancreatic cell population prolonged animal survival and produced human c-peptide in the serum of transplanted animals upon challenge with glucose. Neither prolonged survival nor C-peptide production was observed when the diabetic animals were transplanted with either human foreskin fibroblasts or undifferentiated hESCs. In new updates at the ISSCR Annual Meeting, procedures were described to physically enrich the bud-like clusters to produce cell populations containing as high as 10% insulin positive cells.
"We are currently focusing our efforts on improving both the yields and purities of these islet-like clusters to normalize glucose levels in animal models of diabetes," said Anish Majumdar, Ph.D., Geron's senior director of cell therapy research. This work was performed in collaboration with Dr. Ray Rajotte and Dr. Greg Korbutt at the University of Alberta.
Chondrocytes for Orthopedic Applications
Finally, Geron collaborators at the University of Edinburgh reported the differentiation of chondrocytes from hESCs for use in the repair of diseased or injured articular cartilage. In these studies presented by Dr. Brendon Noble of the University of Edinburgh, hESCs were differentiated into chondrocytes and expressed type II collagen, one of the hallmarks of precursor cells that form cartilage. When the chondrocytes were seeded onto a scaffold matrix and implanted into osteochondral defects in the rat knee, evidence of human cell survival was noted up to 21 days. Animals receiving the hESC-derived chondrocytes showed formation of cartilaginous tissue near the subchondral bone, while control, untransplanted animals showed less cartilaginous tissue.
"These preliminary studies indicate that the implanted hESC-derived chondrocytes can function to produce cartilage," said Dr. Lebkowski. "We now have a renewable source of chondrocytes to enable the development of robust methods to produce articular cartilage of sufficient quality to repair cartilage defects, a major component of multiple forms of arthritis."
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Geron's human embryonic stem cell technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended March 31, 2007.
Source: Geron Corporation
----------------------------------------------
Geron Corporation
David L. Greenwood
Chief Financial Officer
650-473-7765
info@geron.com
or
Russo Partners
LLC
David Schull
858-717-2310 (Media)
david.schull@russopartnersllc.com
Matthew Haines
212-845-4235 (Investors)
matthew.haines@russopartnersllc.com
SIRI 2.90 Volkswagen to Offer SIRIUS Satellite Radio as Standard Equipment on Key Models
Volkswagen of America, Inc. to offer SIRIUS as standard equipment on the 2008 MY Touareg2, New Beetle, New Beetle Convertible, GTI, and GLI
Jun 19, 2007 7:00:00 AM
NEW YORK and AUBURN HILLS, Mich., June 19 /PRNewswire-FirstCall/ -- SIRIUS Satellite Radio (Nasdaq: SIRI) today announced that Volkswagen of America, Inc. will offer SIRIUS as standard equipment in all Touareg2, New Beetle, New Beetle Convertible, GTI, and GLI models beginning with the 2008 model year. SIRIUS will also be available on Jetta, Passat and EOS models.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991118/NYTH125 )
"The Volkswagen of America, Inc. plan to offer SIRIUS as standard equipment in select models not only proves VW's commitment to the customer, but also shows VW's commitment to technology that enhances driving pleasure and enjoyment in every sense," said Adrian Hallmark, Executive Vice President of Volkswagen of America. "SIRIUS Satellite Radio helps to enhance the driving experience and Volkswagen ownership pride."
"Since the first launch on the New Beetle in 2004, to now making it standard on the New Beetle and other key models, VW has always shown to be a significant partner in the growth of SIRIUS," said Mel Karmazin, CEO of SIRIUS. "Volkswagen of America's decision to move in the direction of standardizing SIRIUS on key models only shows their commitment for expansion and growth of our capabilities."
SIRIUS and Volkswagen of America, Inc. announced in March 2006 that Volkswagen will offer SIRIUS as its sole satellite radio provider for vehicles sold in this country through 2012. Volkswagen has exclusively offered SIRIUS beginning with its 2007 model year vehicles and expects to equip approximately 80% of its vehicles with SIRIUS satellite radio receivers. Volkswagen additionally offers three months of complimentary service on vehicles equipped with SIRIUS.
About SIRIUS
SIRIUS, "The Best Radio on Radio," delivers more than 130 channels of the best programming in all of radio. SIRIUS is the original and only home of 100% commercial free music channels in satellite radio, offering 69 music channels. SIRIUS also delivers 65 channels of sports, news, talk, entertainment, traffic, weather and data. SIRIUS is the Official Satellite Radio Partner of the NFL, NASCAR, NBA and NHL, and broadcasts live play-by- play games of the NFL, NBA and NHL, as well as live NASCAR races. All SIRIUS programming is available for a monthly subscription fee of only $12.95.
SIRIUS Internet Radio (SIR) is a CD-quality, Internet-only version of the SIRIUS radio service, without the use of a radio, for the monthly subscription fee of $12.95. SIR delivers more than 75 channels of talk, entertainment, sports, and 100% commercial free music.
SIRIUS products for the car, truck, home, RV and boat are available in more than 25,000 retail locations, including Best Buy, Circuit City, Crutchfield, Costco, Target, Wal-Mart, Sam's Club, RadioShack and at shop.sirius.com.
SIRIUS radios are offered in vehicles from Audi, Bentley, BMW, Chrysler, Dodge, Ford, Infiniti, Jaguar, Jeep(R), Land Rover, Lexus, Lincoln, Mercury, Maybach, Mazda, Mercedes-Benz, MINI, Mitsubishi, Nissan, Rolls Royce, Scion, Toyota, Volkswagen, and Volvo. Hertz also offers SIRIUS in its rental cars at major locations around the country.
Click on www.sirius.com to listen to SIRIUS live, or to purchase a SIRIUS radio and subscription.
Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, future events or performance with respect to SIRIUS Satellite Radio Inc. are not historical facts and may be forward-looking and, accordingly, such statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, any such statements are qualified in their entirety by reference to the factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission. Among the significant factors that could cause our actual results to differ materially from those expressed are: our pending merger with XM Satellite Radio Holdings, Inc. ("XM"), including related uncertainties and risks and the impact on our business if the merger is not completed; any events which affect the useful life of our satellites; our dependence upon third parties, including manufacturers of SIRIUS radios, retailers, automakers and programming providers; and our competitive position versus other audio entertainment providers.
O-SIRI
MEDIA CONTACT:
Patrick Reilly
SIRIUS
212 901 6646
preilly@siriusradio.com
Sal Resendez
SIRIUS
646 313 2405
sresendez@siriusradio.com
SOURCE SIRIUS Satellite Radio
----------------------------------------------
Patrick Reilly
+1-212-901-6646
or preilly@siriusradio.com
or Sal Resendez
+1-646-313-2405
or sresendez@siriusradio.com
both of SIRIUS Satellite Radio
SGMO 8.19 Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
Successful Application of Sangamo's ZFP Technology to Two Crop Species
Jun 19, 2007 7:00:00 AM
INDIANAPOLIS, Ind. and RICHMOND, Calif., June 19 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the successful completion of research milestones as part of their joint Research and Commercial License Agreement. These milestones represent the successful application of Sangamo's zinc finger DNA-binding protein (ZFP) technology to the generation of specific traits in two major crop species -- maize and canola.
"Our collaboration with Sangamo has been extremely positive, and we continue to be very excited by the precision and promise of this technology," said Dan Kittle, vice president, Research and Development for Dow AgroSciences. "These milestones demonstrate the ability of ZFP Nucleases (ZFNs(TM)) to act precisely at their intended target in canola and corn, crops of commercial importance, not model systems, and represent the first demonstration of the precise placement of a gene of interest into a specific native gene in maize. This is a development that has potentially significant impact on the cost and timelines of generating crop products with new and improved traits. In addition, Sangamo's technology holds the potential to enable gene editing of native traits and up- and down-regulation of genes to influence metabolic profiles of plants. Everything that we have seen and everything that we have done only reinforces our enthusiasm and commitment to this technology."
"Our ZFP technology can be used to specifically regulate and modify genes," said Philip Gregory, D. Phil., Sangamo's vice president of research. "We have already demonstrated the utility of our ZFN 'genome editing' technology in human cells. Moreover, this technology has the unique advantage of generating the desired trait outcomes without needing to be permanently present in the modified cells. In applying engineered ZFNs to crop plants, Dow AgroSciences scientists have built upon our experience in developing ZFP technology for human therapeutics and accomplished a series of 'scientific firsts.'"
These milestones include the first demonstration of ZFN-mediated targeted integration of DNA into a native gene in maize and the first demonstration of targeting a native gene in canola with ZFNs.
Sangamo scientists recently published data [in Proceedings of the National Academy (PNAS (2007) 104: 3055)] demonstrating the introduction of a "gene-sized fragment" of DNA into a specific location in the human genome via ZFN-mediated targeted gene addition. Dow AgroSciences scientists have similarly used Sangamo-designed ZFNs to successfully target native genes in crops with extraordinary molecular precision.
"Dow AgroSciences has had the foresight to recognize the power of our ZFP technology and the expertise to implement it successfully into its precision trait development program," said Edward Lanphier, Sangamo's president and chief executive officer. "In our research partnership we are rapidly developing innovative applications in plant biotechnology."
The three-year agreement initiated October 2005, provides Dow AgroSciences with access to Sangamo's proprietary ZFP technology for the development of products in plants and plant cell cultures. During the initial three-year research term, Dow AgroSciences has the option to obtain a commercial license to sell products incorporating or derived from plant cells generated using Sangamo's ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals.
ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. The ability to selectively control specific genes is emerging as a critical tool in modern biotechnology. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. By engineering ZFPs that recognize a specific DNA sequence Sangamo scientists have created ZFP transcription factors (ZFP TFs(TM)) that can control gene expression and consequently, cell function. For example, Sangamo has demonstrated that plant oils can be improved using ZFP TFs.
Sangamo has also developed sequence-specific ZFNs(TM) for precision gene modification and targeted gene insertion. These technologies have the potential to play a major role in bringing new discoveries in genomics forward to the marketplace. The use of Sangamo's ZFP technology to enable the efficient and reproducible generation of combinations or stacks of multiple traits and the insertion of new traits could address increasing demand.
About Dow AgroSciences LLC
Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top tier agricultural company providing innovative crop protection, seeds, and biotechnology solutions to serve the world's growing population. A wholly owned subsidiary of The Dow Chemical Company, global sales for Dow AgroSciences are $3.4 billion. Visit http://www.dowagro.com for more information.
About Sangamo BioSciences, Inc.
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. A portion of Sangamo's research in plant agriculture is supported by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology. Sangamo has also established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.
This press release may contain forward-looking statements based on Dow AgroSciences LLC and Sangamo BioScience, Inc.'s current expectations. These forward-looking statements include, without limitation, references to the achievement of additional milestones under the Research and Commercial License Agreement and the application of Sangamo's ZFP TFs and ZFNs in plant agriculture. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Dow AgroSciences ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Dow AgroSciences and Sangamo BioSciences, Inc. assume no obligation to update the forward-looking information contained in this press release.
(TM) Trademark of Sangamo Biosciences, Inc.
SOURCE Sangamo BioSciences, Inc.
----------------------------------------------
Robyn Heine of Dow AgroSciences LLC
+1-317-337-4807
Rheine@dow.com; or Elizabeth Wolffe
Ph.D.
of Sangamo BioSciences
Inc.
+1-510-970-6000
ext. 271
ewolffe@sangamo.com; or Justin Jackson of Burns McClellan
Inc.
+1-212-213-0006
jjackson@burnsmc.com
for Sangamo BioSciences
Inc.
CRUS 8.11 Cirrus Logic CobraNet Technology on Wide Display at InfoComm 2007
Jun 18, 2007 9:27:00 AM
Copyright Business Wire 2007
Cirrus Logic Inc. (NASDAQ:CRUS):
Who: Cirrus Logic develops high-precision, analog and mixed-
signal integrated circuits (ICs) for a broad range of
consumer and industrial markets.
What: CobraNet(R) technology, the leading standard for networked
digital audio over Ethernet, will be prominently featured
at the 2007 InfoComm, June 19 - 21, 2007, Anaheim,
California.
In the Cirrus Logic/CobraNet booth #9120, InfoComm
attendees will learn more about the growing variety of
networked audio equipment that feature CobraNet
technology, as well as the expanding name-brand list of
installations worldwide that leverage CobraNet's unique
features for managing digital audio networks using
standard Ethernet equipment. Included in this CobraNet
"Wall of Fame" is networked audio equipment from such
well-known original equipment manufacturers (OEMs) as
Biamp Systems, Harman Pro/Crown, Meyer Sound
Laboratories, Peavey MediaMatrix, QSC Audio and Symetrix
SymNet.
Further, at this year's InfoComm, Cirrus Logic will also
launch CobraNet Discovery, a unique software network
management tool that identifies and displays all CobraNet
devices on a network, allowing for real-time monitoring
and display of useful data to maintain the health and
status of CobraNet devices.
Cirrus Logic's CobraCom(TM), a reference platform for
developing CobraNet-enabled digital audio network
devices, will also be exhibited.
Cirrus Logic CobraNet leaders also plan to deliver several
InfoComm seminars designed to inform and expand show
participants' knowledge about the benefits of digital
audio networking with CobraNet technology.
Topic: Introduction to Digital Audio Networking
Date: June 19, 2007
Time: 1:30 p.m. - 3:30 p.m.
Presenter: Steve Bassett, CobraNet Marketing Manager
Description: Introduction to Digital Audio Networking
(using CobraNet as an example) is designed for
audiovisual and information technology professionals who
need a basic understanding of networked digital audio and
the CobraNet technology employed by many commercial audio
equipment manufacturers.
Topic: Advanced Topics in CobraNet Network Applications
Date: June 20, 2007
Time: 10:30 p.m. - 12:30 p.m.
Presenter: Steve Gray, CobraNet Applications Manager
Description: This seminar is designed for audiovisual and
information technology professionals who have a basic
understanding of or experience with networked digital
audio (using CobraNet as an example). It builds upon the
seminar "Introduction to Network Digital Audio with
CobraNet" by presenting the next level of detail in the
CobraNet protocol, networking topology, and
recommendations for designing and commissioning CobraNet
audio networks.
When/Where: InfoComm 2007
-- June 19-21, 2007
-- Anaheim Convention Center - Anaheim, Calif.
http://www.infocomm.org
Cirrus Logic Media Relations Information contact: Jody Privette, 415-328-4700 or jprivette@strategiccom.biz, or visit www.cirrus.com.
Cirrus Logic, Cirrus and CobraNet are trademarks of Cirrus Logic Inc. All other product names noted herein may be trademarks of their respective holders.
Source: Cirrus Logic Inc.
----------------------------------------------
Cirrus Logic
Inc.
Austin
Bill Schnell
512-694-4236
or
SCI
Jody Privette
415-328-4700